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Aims: Ischaemic postconditioning (IPostC) is a powerful phenomenon that 
harnesses the body‟s innate system to protect the myocardium against ischaemia/ 
reperfusion injury. The precise signalling mechanisms that elicit this cardioprotective 
effect are unclear but suggest a key role for the cell protective Reperfusion Injury 
Salvage Kinase (RISK) pathway that activates Akt and extracellular signal-regulated 
kinase-1/2 (Erk1/2). Recently, the powerful prosurvival path named as the Survivor 
Activation Factor Enhancement (SAFE) pathway, and involving activation of tumour 
necrosis factor-alpha (TNFα) and signal transducer and activator of transcription-3 
(STAT-3) has been identified in ischaemic preconditioning. In this thesis, we 
investigated the role of the SAFE pathway in ischaemic and pharmacological 
postconditioning. Pharmacological postconditioning was achieved with sphingosine-
1-phosphate (S1P), a constituent of high density lipoprotein (HDL), or with classic 
preconditioning pharmacological agents such as bradykinin, adenosine and opioids. 
Furthermore, we also proposed to investigate a possible interplay between the SAFE 
and the RISK pathways in S1P mediated cardioprotection against reperfusion injury. 
Methods: Isolated mouse hearts from TNFα knockout (TNFα-/-) and cardiomyocyte-
specific STAT-3 knockout (STAT-3-/-) were subjected to an ischaemia/ reperfusion 
insult and postconditioned with brief periods of ischaemia, bradykinin (100 nM), a 
specific delta opioid agonist, D-Ala 2‟, D-Leu 5‟- enkephalin acetate salt (DADLE, 
100 nM), adenosine (100 µM), HDL (200 µg/ml) or sphingosine-1-phosphate (10 
nM). Hearts were stained with triphenyltetrazolium chloride and infarct size was 
analyzed with computerized planimetry. Cytosolic, nuclear and mitochondrial protein 
levels of STAT-3, Akt, and Erk1/2 were determined by western blot analysis. 
Results: Ischaemic postconditioning and all pharmacological postconditioning 
mimetics reduce infarct size in WT mice but failed to protect STAT-3-/- and TNFα-/- 
mice (except for adenosine in TNFα-/-). This protective effect was associated with a 
phosphorylation and therefore activation of nuclear and/ or mitochondrial STAT-3. 
Inhibition of the RISK path in S1P induced cardioprotection resulted in a lack of 
activation of the SAFE path, and vice versa. Furthermore, the RISK path failed to be 
















Conclusion: Our data revealed a critical role for TNF and STAT-3 in ischaemic and 
pharmacological postconditoning-induced cardioprotection. The dual activation of the 
SAFE and RISK pathways confirms the existence of multiple prosurvival pathways 




























































1.0 Global Implications for cardiovascular disease 
In 1628, William Harvey made the profound discovery of the human blood circulatory 
system setting in motion an ideology that was further built upon and is still upheld by 
the medical world today (Garber, 2008). He described the heart as a pump through 
which blood was continually circulated from the heart to the lungs and back to the 
heart and then through the body. The concept of cardiovascular disease, at the time 
was barely fathomable.  
However, this changed with the arrival of the 20th century. Due to the increase in 
industrialization, urbanisation and lifestyle changes, cardiovascular disease became 
the dominant disease in the world. Today, it accounts for approximately 30 percent 
of deaths worldwide (Libby, 2008).  
Cardiovascular disease (CVD) is a broad term that describes diseases affecting the 
heart and its circulatory system. Commonly, it refers to those related to 
atherosclerosis (the hardening of arteries or blood vessels due to the accumulation 
of fatty deposits). These include coronary heart disease, stroke and inflammatory 
heart disease. Amongst them, ischaemic heart disease (IHD) is one of the most 
prevalent and is predicted by the World Health Organisation (WHO) to become the 
leading global burden by 2030 (Mathers and Loncar, 2006). 
Fifty years ago, ischaemic heart disease was considered rare in sub-Sahara Africa. 
Today, it has emerged as the eighth leading killer in this region. In people over 60 
years, IHD is ranked as the leading cause for mortality in men and  second in woman 
(Figure 1) (Mensah, 2008). The increase in high blood pressure, diabetes mellitus, 
tobacco use, obesity and dyslipidemia are contributing factors of atherosclerosis 
which have impacted on the escalating rate of IHD (Reddy and Yusuf, 1998). 
Furthermore, a study conducted by the Medical Research Council (MRC) listed IHD 


















Fig 1. Ischaemic heart disease has been ranked as the leading cause of cardiovascular 
disease mortality by the South African Medical Research Council.  Adapted from (Norman et al., 
2007). 
 
1.1 Ischaemic heart disease 
Ischaemic heart disease is characterized as the reduced supply of oxygenated blood 
to the myocardium (heart muscle) and is caused by the partial or complete 
obstruction of a coronary artery to the heart (Opie, 2004). If this coronary occlusion is 
allowed to persist, the resultant dead cells form an infarct that may proceed to total 
necrosis (Figure 2). Additional pathology includes ischaemia-induced contractile 
dysfunction and hypertrophy.  Therefore, it is vital that a timely intervention be 
implemented to restore the blood flow and rescue the ischaemic myocardium from 

















Fig 2. Coronary artery occlusion leads to development of a myocardial infarction. Obstruction of 
oxygenated blood flow causes myocardial necrosis and eventually ischaemic heart disease. 
(http://nursingcrib.com/nursing-care-plan/nursing-care-plan-myocardial-infarction/) 
 
2.0 Reperfusion Injury 
Restoration of coronary blood flow following ischaemic injury may be accomplished 
by myocardial reperfusion. This procedure is achieved via thrombolytic therapy (use 
of pharmacological agents to break the blood clot) or primary percutaneous coronary 
intervention (PCI, insertion of a stent to open the affected artery via balloon 
angioplasty). Paradoxically, these effective strategies used to reduce the myocardial 
infarct size, cause reperfusion injury and reduce the beneficial effects of reperfusion. 
Lethal reperfusion injury causes the functional impairment of myocardial contractility 
(stunning), arrhythmia and death of cardiomyocytes which further increases infarct 
size (Opie, 1989, Opie, 2004). The additional release of reactive oxygen species 
(ROS) and calcium overloading upon reperfusion is also detrimental to the 
myocardium (Zweier, 1988, Kloner, 1993, Piper et al., 1998). 
 Three potential initial causes of lethal reperfusion injury exist, aside from ROS. They 
are, as follows (Piper et al., 1998): 
1) The re-energization of the ischaemic cell. Upon reperfusion, oxygen is 
resupplied to the mitochondria which lead to the hypercontracture of cardiomyocytes 
















Mitochondria are responsible for the production of ATP which is synthesised by 
means of the oxidative phosphorylation. During ischaemia, calcium and sodium 
accumulate within the cytosol of myocardial cells. Reoxygenation as a result of 
reperfusion reactivates the calcium pump of the sarcoplasmic reticulum and the 
sodium pump of the sarcolemma which function to restore the homeostasis of these 
ions within the mitochondria and cytosol. However, if the pumps are damaged during 
the ischaemic event, the imbalance would lead to intracellular calcium overload and 
ATP production would cease. In addition, hypercontracture of the sarcolemma could 
lead to membrane rupture and cell death. 
 
2) The rapid normalization of tissue pH. The intercellular and interstitial space 
acidosis that is caused by the anaerobic metabolism during the prolonged ischaemia 
is disrupted by reperfusion. In an attempt to restore pH balances, calcium overload 
may occur and cause increased hypercontracture and cell injury. 
The cytosolic and intracellular pH is lowered to acidic levels during ischaemia as a 
consequence of anaerobic metabolism and breakdown of ATP. Reperfusion leads to 
the activation of the sodium/ hydrogen exchanger and bicarbonate/sodium symporter 
which function to reduce the acidity. During this pH restoration, the sodium/ calcium 
pump may be activated and the attempt to remove excess sodium from the cell may 
cause an intracellular calcium overload. 
 
3) The rapid normalization of tissue osmolality. During ischaemia, there is an 
accumulation of end-products from anaerobic metabolism in the intracellular and 
extracellular space. The extracellular osmolality is rapidly normalized by reperfusion 
and thus a transsarcolemmal osmotic gradient is created. This leads to cell swelling 
and fragility which favour rupture of the sarcolemma. 
These events may be further propagated by cell-to-cell interactions and eventually 
progress to necrosis. A high concentration of reactive oxygen species can also 
cause lead to greater infarct size by causing membrane lipid and DNA oxidation 
(Zweier et al., 1987). Experimental studies with Heptanol, a gap junction uncoupler 
during the first minutes of reperfusion, limited the spread of necrosis and significantly 
















Dorado et al., 1997). It was important to find the correct intervention that reduced 
and did not simply delay the manifestation of irreversible injury. 
 
3.0. The Concept of Conditioning 
3.1. Definition: Ischaemic pre- and postconditioning 
Over the past few decades, considerable attention has been focused on the 
development of novel strategies to attenuate myocardial ischaemia-reperfusion injury 
and improve the outcome post-MI. Acute myocardial infarction (AMI) by prolonged 
ischaemia resulted in severe necrosis whereby dead cells were unable to be 
replenished by division of surviving cardiomyocytes. The unsatisfactory benefit of 
reperfusion therapy contributed more than alleviated the myocardial infarct size. 
In 1986, Murry et al. published a seminal paper in which they described a 
phenomenon whereby four cycles of five minutes of ischaemia with intermittent 
reperfusion prior to a subsequent and prolonged ischaemia attenuated infarct size by 
75% in the canine myocardium.  Initially, they found that brief periods of ischaemia 
reduced the rate of adenosine triphosphate (ATP) depletion during subsequent 
ischaemic episodes (Reimer et al., 1986).  Intermittent reperfusion also served to 
prevent the cumulative effects of ischaemic injury by washing out potentially harmful 
catabolites such as lactate, hydrogen ions (H+) and ammonia (NH4).  The reduction 
in ATP depletion was associated with the limitation in infarct size.  Given these 
findings and that the procedure could be reproduced successfully, this 
cardioprotective phenomenon was termed „ischaemic preconditioning‟ (IPC) (Murry 
et al., 1986).   
This model of cardioprotection is referred to as „classic‟ or early preconditioning and 
is initially transient, with preconditioned state lasting for only 1-2 hours (Figure 3) 
(Murry et al., 1991).  However, within 24 hours of the preconditioning stimulus, a late 
phase of protection, known as delayed preconditioning,  is evident but is less robust 
and more prolonged, lasting up to 72 hours after the preconditioning stimulus (Baxter 
















Fig 3. Schematic representation of classic and delayed preconditioning 
 
Since its inception, researchers have experimented with ischaemic preconditioning in 
different animal models and conditions to elucidate a possible signalling mechanism. 
The discovery of a signal transduction pathway would allow for the development of 
novel drug therapeutics. The protective benefits of IPC have also been successfully 
reproduced with the introduction of a pharmacological agent stimulus prior to the 
ischaemic event. Adenosine, bradykinin and opioids were among the early agonists 
that mimicked IPC and are discussed later in this section. 
Ischaemic preconditioning demonstrated that brief episodes of ischaemia could 
protect the myocardium from a subsequent lethal ischaemic event (Murry et al., 
1986). Although researchers have been consumed with delineating its signalling 
mechanisms and discovering pharmacological mimetics in the past decade, it is 
impossible to predict the index ischaemic period. This unpredictability makes 
preconditioning a difficult strategy to implement in a clinical setting against 
myocardial ischaemia/ reperfusion injury. However, targeting the reperfusion phase 
is an appealing option. In 2003, Vinten-Johanssen‟s group elucidated that subjecting 
the in vivo canine myocardium to 3 x 30 second ischaemic episodes with intermittent 
reperfusion, dramatically reduced myocardial infarct size (Zhao et al., 2003). The 
observed levels of cardioprotection induced by this phenomenon termed as 
ischaemic postconditioning (IPostC) were strongly comparable to those in 
preconditioning (Figure 4).  
The protective benefits of IPostc have also been established in other animals such 
as rats, mice, rabbits and pigs (Kaljusto et al., 2006, Schwartz and Lagranha, 2006, 
Ischaemia: Ischaemic preconditioning 
Drug: Pharmacological  preconditioning 
< 4 hours: classic preconditioning 

















Skyschally et al., 2009, Yang et al., 2004). Interestingly, infarct size reductions by 
IPostC in large animals such as dogs (50-80%) are greater than in smaller animals 
(mice, rats and rabbits (~30%). This is more variable than the 50-80% infarct sparing 
effect in preconditioning (see review, (Vinten-Johansen et al., 2007)). Halkos et al. 
found that IPC and IPostC offered similar levels of protection in the canine model but 
not in the rat model where IPC yielded a greater protection (Halkos et al., 2004). It is 
possible that a species discrepancy may exist which may be due to metabolic or 
genetic differences and that an adjustment in the IPostC algorithm may be required. 
Nevertheless, IPostC displays a promising clinical strategy in the attenuation of 
acute myocardial infarction. 
 
Fig 4. Schematic representation of a postconditioning protocol 
 
3.2 Clinical relevance 
Percutaneous coronary intervention (PCI) and thrombolytic agents are used to 
restore reperfusion and reduce infarct size in patients presenting with an acute 
myocardial infarction. However, lethal reperfusion Injury occurs, leading to structural 
and functional damage to the myocardium, as discussed earlier. Ischaemic 
preconditioning has been demonstrated to be highly effective in reducing infarct size 
and improving functional recovery in the heart. The unpredictable nature of 
prolonged ischaemia limits the application of preconditioning in clinical practice. 
Preconditioning may be implemented in surgery where it is expected to be a long 
ischaemia such as during cardiac bypass or transplantation surgery. No 
foreknowledge is required with postconditioning. In 2005, Staat et al conducted a 
clinical trial that examined the prospect of postconditioning in patients with AMI who 
were randomized to receive four 1 minute cycles of inflation-deflation with an 
angioplasty balloon following stent placement. Infarct size was successfully reduced 
















Although small clinical proof-of-concept studies suggest that ischemic 
postconditioning can protect the human heart against lethal reperfusion injuries, 
larger clinical trials testing ischemic or pharmacological postconditioning are needed 
to test the clinical outcome of this phenomenon. 
 
3.3. Mechanisms of Conditioning 
3.3.1 G-Protein coupled receptors  
G-protein coupled receptors (GPCRs), also known as the seven-transmembrane 
domain receptors (7TM) or serpentine receptors, are a diverse and abundant type of 
cell surface receptors found in eukaryotes (Hall et al., 1999). Structurally, they 
consist of seven alpha-helical protein domains that span the cell membrane, with an 
extracellular amino terminus and a cytosolic carbon terminus (Figure 5) (Schertler et 
al., 1993, Palczewski et al., 2000).  
 
Fig 5. Structure of a typical G coupled protein receptor. GCPRs contain seven transmembrane 
domains, with an extracellular amino terminus and an intracellular carboxyl terminus. (http://images-
mediawiki-sites.thefullwiki.org/03/9/1/2/441015484151498.gif) NH2, amino terminus; COOH, carboxyl 
terminus 
GPCRs are receptors for G proteins which belong to a superfamily of proteins that 
bind guanine triphosphate (GTP), guanine diphosphate (GDP) or guanine 
nucleotides. Upon ligand binding, the GPCR undergo a conformational change which 
is transmitted throughout the helices to the cytosolic side of the membrane (Figure 
















G proteins by catalyzing the exchange of GTP for GDP. GPCRs are deactivated by 
phosphorylation of serine or threonine residues in their C-terminus (Libby, 2008, 
Hermans, 2003). The active trimeric GTP-bound G protein disassociates into Gα-
GTP and Gβ,γ-GTP subunits. The Gα-subunit switches on the target before it is 
hydrolyzed to return the G protein to its inactive form i.e as GDP-bound G protein. 
The stimulatory Gs protein and inhibitory Gi protein are both activated via this 
mechanism but exert opposite effects on the same system. For example, The alpha 
unit of Gs, in combination with GTP enhance the activity of adenyl cyclase 
(responsible for production of second messenger, cyclic adenosine monophosphate 
(cAMP) that is indirectly required for contractile activity) which is inhibited by the Gi 
(Ross and Gilman, 1980). G-protein coupled receptors play an important role in the 
signal transduction processes concerned with mediating cardioprotection. 
 
Fig 6. The GDP/GTP- bound G protein cycle (http://en.wikipedia.org/wiki/G_protein) 
GPCRs involvement in postconditioning require that 1) the receptors must reside in 
the target tissue (in this case, the myocardium); 2) the ligand is endogenously 
produced and increased either during ischaemia or reperfusion; 3) the ligand-
receptor interactions may be inhibited either pharmacologically or via genetic 
knockout or silencing ribonucleic acid (SiRNA) models; and 4) exogenous addition of 
















Johansen et al., 2007)). Adenosine, bradykinin and opioids receptors are discussed 
later in this thesis with regard to postconditioning. 
 
3.3.2. The RISK pathway 
The Reperfusion Injury Salvage Kinase (RISK) pathway consists of protein kinases, 
phosphatidylinositol 3-kinase (PI3-K), Akt, extracellular regulated kinases (ERK) and 
glycogen synthase kinase-3β (GSK-3β) (Hausenloy and Yellon, 2004, Yellon and 
Baxter, 1999). The involvement of these kinases was postulated based on their 
prosurvival properties against reperfusion injury (Yellon and Baxter, 1999). 
PI3-K/Akt was first shown to be activated by phosphorylation following an ischaemic 
preconditioning stimulus in the isolated rat heart (Tong et al., 2000). Inhibition of PI-
3K with Wortmannin or LY 294002 abolished IPC induced protection. Although 
ERK1/2 was also phosphorylated in response to an IPC stimulus before the 
prolonged ischaemic event (Fryer et al., 2001), we and others have shown that 
inhibition of ERK1/2 did not influence the preconditioning outcome (Somers, 2009). 
These kinases have also been investigated as potential mediators of IPC at the time 
of reperfusion in a rat heart model (Hausenloy et al., 2005a). This infarct limiting 
study involved the inhibition of PI3K/Akt and ERK with LY 294002 and PD 98059, 
respectively. Activation of these prosurvival kinases prior to the index ischaemia and 
at the time of reperfusion could imply a biphasic response to IPC. It has been 
suggested that the early activation during the IPC stimulus would serve as a primer 
for the kinase phosphorylation observed at the time of reperfusion (Hausenloy et al., 
2005b). Alternatively, an intermediary such as adenosine or ROS may exist to 
facilitate this prosurvival mechanism.  
Inhibition of PI3-K at reperfusion with wortmannin or LY 294002 abrogated the 
postconditioning effect in the isolated perfused rat heart (Tsang et al., 2004). The 
involvement of the PI3-K/Akt pathway was confirmed by Yang et al. in the isolated 
perfused rabbit heart model (Yang et al., 2005). This group also reported a loss of 
IPostC induced protection with the inhibition of the MEK/Erk 1/2 pathway by the MEK 
inhibitor PD 98059 (Yang et al., 2004). In contrast, Darling et al. reported that there 
















inhibition by LY 294002 but PD 98059 abrogated the infarct sparing effect of IPostC 
(Darling et al., 2005). 
Glycogen synthase kinase 3 belongs to a family of conserved serine/threonine 
kinases present in eurkaryotes. It exists in two isoforms in humans, i.e GSK-3α (51 
kDa) and GSK-3β (47 kDa) (Grimes and Jope, 2001, Harwood, 2001). Although both 
isoforms are expressed in the heart, GSK-3β is the most extensively studied (Henry 
and Killilea, 1994). GSK-3β was originally described for its ability to inhibit glycogen 
synthesis (Embi et al., 1980) but has since been discovered to be involved in a host 
of cell functions, including metabolism, gene expression and cell integrity (Grimes 
and Jope, 2001). 
GSK-3β is constitutively active in the cytosol of cardiomycytes. Upon 
phosphorylation at its serine 9 residue, GSK-3β is rendered inactive. This 
phosphorylation may be achieved by multiple pro-survival signalling kinases such as 
Akt, Protein Kinase C (PKC), or ERK, in the reduction of ischaemia reperfusion injury 
(Murphy and Steenbergen, 2007, Sugden et al., 2008, Tong et al., 2002).  
Additionally, the inactivation of GSK-3β also inhibits the opening of the mitochondrial 
permeability pore (discussed later in this chapter). Murphy et al. established that 
phosphorylation of the serine 9 residue by ischaemic preconditioning led to inhibition 
of GSK-3β (Tong et al., 2002). Additionally, the isoform non-selective 
pharmacological inhibition of GSK-3 also protected against ischamia reperfusion 
injury and successfully reduced infarct size. 
Downstream prosurvival factors of the RISK pathway such as p70S6 kinase, PKCε, 
endothelial nitric oxide synthase (eNOS) and GSK-3β are potential mediators of 
IPostC induced protection (Hausenloy and Yellon, 2006, Burley and Baxter, 2009, 
Gomez et al., 2008). It is likely that these downstream targets of the RISK pathway 
may also be involved in the inhibition of apoptosis rather than directly by the RISK 
pathway, itself. 
 
3.3.3. The role of mitochondria in conditioning 
Mitochondria are prominently known as the energy powerhouses of the cell. They 
















(Citric Acid cycle) which is used to drive metabolic processes, including regulation of 
membrane potential; apoptosis programmed cell death and calcium signalling. The 
cardioprotective properties of the mitochondria have piqued the interests of many 
researchers who believe the organelle to be the final deciding factor or end effector 
in mediating a successful recovery from ischaemic damage. This benefit would be 
attributed to the opening of the mitochondrial adenosine triphosphate dependant 
potassium channel (mitoKatp) and closure of the permeability transition pore 
(mPTP). 
 
3.3.3.1 Mitochondrial adenosine triphosphate dependent potassium channel 
Activation of the mitoKATP channel plays an important role in preconditioning. It was 
first discovered by Gross et al. who demonstrated glibenclamide, a KATP antagonist 
blocked the protective effects of preconditioning in dog hearts (Gross and 
Auchampach, 1992). At the time, it was unknown that KATP channels existed in both 
the sarcolemma and mitochondria. This was later clarified with use of different 
models, attributing the cardioprotective role to the mitoKATP channel (Gross and 
Fryer, 1999, Garlid et al., 1997, Liu et al., 1998).  
ATP is synthesized from ADP in the mitochondria by the re-entry of H+ via the F1 
apparatus along a strong electrochemical gradient. The opening of the mitoKATP 
allows for the inflow of potassium into the mitochondria. The intracellular potassium 
is exchanged for extracellular H+ by the potassium/hydrogen exchanger located on 
the inner mitochondrial membrane. Hence, the H+ enters the mitochondria by means 
of skipping the F1 apparatus and ATP production is reduced (Oldenburg et al., 
2002a). The structure of the mitoKATP has never been identified. 
Interestingly, the opening of the mitoKATP channel has been linked to the release of 
reactive oxygen species. Diazoxide, a mitoKATP channel activator, induced a 
preconditioning benefit which was abolished with the addition of a free radical 
scavenger, N-acetylcysteine (NAC) (Forbes et al., 2001). Inhibition of PI-3 Kinase 
with wortmannin did not block the increased fluorescence of diazoxide (ROS 
measured with MitotrackerTM probe), suggesting that mitoKATP channel would be 
















is also closely involved in preconditioning. When PKC was downregulated with 
phorbol 12-myristate 13-acetate, diazoxide failed to activate the mitoKATP channels 
and precondition the rat heart (Wang et al., 2001b). This would suggestively rule out 
mitoKatp as the end effector for preconditioning mediated cardioprotection since 
PKC signalling would be downstream of mitoKATP channels. 
Blockade of the mitoKATP by glibeclamide or 5-hydroxydeconoate (5-HD) abolished 
the postconditioning effect in rabbit and pig hearts (Iliodromitis et al., 2006, Yang et 
al., 2004, Yang et al., 2005). Pharmacological postconditioning with isoflurane, a 
volatile halogenated anesthetic, limited infarct size (Chiari et al., 2005, Feng et al., 
2005, Krolikowski et al., 2005). This beneficial effect involved the activation of the 
PI3-K/Akt pathway, GSK-3β inactivation and inhibition of the mPTP opening. 
Inhibition of the mitoKATP channel abrogated the infarct sparing effect. 
 
3.3.3.2 Mitochondrial permeability transition pore 
The mitochondrial permeability transition pore (mPTP) is a non-specific channel of 
the inner mitochondrial membrane. The opening of this channel via a stressful event 
such as ischaemia-reperfusion injury would mediate cell death as a result of 
uncoupling oxidative phosphorylation and induced mitochondrial swelling (Griffiths 
and Halestrap, 1995, Hausenloy et al., 2003, Halestrap et al., 2004). Controversy 
surrounds the structure of the mPTP. Its core components were originally perceived 
to consist of voltage- dependant anion channel (VDAC), adenine nucleotide 
translocator (ANT) and cyclophilin D (CYP-D). However, knockout studies seem to 
suggest the exclusion of VDAC and ANT (Baines et al., 2007, Kokoszka et al., 
2004). CYP-D is still considered an important regulatory component of the mPTP as 
CYP-D deficient mice subjected to calcium or oxidative stress failed to induce 
opening of the pore and smaller infarcts were recorded in response to ischaemia-
reperfusion injury (Basso et al., 2005, Baines et al., 2005, Nakagawa et al., 2005). 
A cardioprotective strategy against reperfusion injury that harnessed this information 
involved the transient opening and closure of the mPTP. The infusion of a mPTP 
inhibitor, cyclosporine-A (CsA), at reperfusion protected the isolated rat heart 
















end effector of ischaemic preconditioning (Hausenloy et al., 2004, Javadov et al., 
2003). The precise signalling mechanism by which IPC inhibits the mPTP opening 
remains to be determined although it is likely that protein kinases such as Akt 
(Bopassa et al., 2006) or GSK-3β are involved (Juhaszova et al., 2004).  
In 2005, Argaud et al. demonstrated the IPostC induced inhibition of the mPTP in 
isolated rabbit heart mitochondria (Argaud et al., 2005). The PI3-K/Akt pathway was 
implicated as an important IPostC mediator of mPTP inhibition when inhibition of the 
prosurvival pathway with wortmannin or LY 294002 prevented the inhibitory effect of 
IPostC on the mPTP opening (Bopassa et al., 2006). Cyclophilin-D (CYP-D) is a 
matrix protein that binds to the inner mitochondrial membrane in a calcium and 
inorganic phosphate regulated process, to facilitate the opening of the mPTP (Di Lisa 
and Bernardi, 2009). Postconditioning by inhibition of the mPTP with cyclosporine-A 
(CsA) or IPostC in CYP-D-/- mice, successfully reduced infarct size (Lim et al., 2007). 
Inhibition of the mPTP represents a promising therapeutic target for cardioprotection. 
Piot et al conducted a pilot trial to investigate the potential attenuation in infarct size 
in AMI patients following CsA treatment (Piot et al., 2008). CsA was administered as 
an intravenous bolus immediately before coronary artery reperfusion by PCI. Infarct 
size was assessed by the release of creatine kinase and troponin I during the first 
three days of reperfusion and by MRI at day 5 after infarction. Based on the results, 
the authors concluded that CsA administration at reperfusion successfully reduced 
infarct size and a larger study was suggested to confirm the findings. 
 
4.0. Pharmacological conditioning agents 
Translating ischemic pre- and postconditioning from bench to bedside can be 
difficult. Patients exhibiting different co-morbidities may negate the protective effects. 
Therefore, pharmacological conditioning presents the advantage of being applied in 
AMI patients with or without PCI. 
4.1. Adenosine 
Adenosine is a purine nucleoside and occurs naturally in the intra- and extracellular 
space, produced either by 5‟-nucleotidase which dephosphorylates AMP or by the 
















have been shown to be elevated during ischaemia and early reperfusion (Schrader 
et al., 1977, Miller et al., 1979). It exerts its effects via the activation of its G-coupled 
protein receptors: A1, A2A, A2B and A3 adenosine receptor (AR) subtypes, located in 
the myocardium and vasculature (Cohen and Downey, 2008). These receptors 
mediate various responses such as modulation, coronary flow, heart rate, 
contraction and cardioprotection. Olafsson et al. reported that an infusion of 
adenosine during reperfusion limited infarct size and improved ventricular function in 
the canine myocardium (Olafsson et al., 1987). Preconditioning with adenosine 
successfully reduced infarct size (Liu et al., 1991) and subsequent investigations 
confirmed protection with pre-ischaemic A1  and A3AR agonism (Liu and Downey, 
1992, Lasley and Mentzer, 1992, Thornton et al., 1992, Strickler et al., 1996, Carr et 
al., 1997, De Jonge et al., 2002, Liu et al., 1994, Tracey et al., 1997, Liang and 
Jacobson, 1998, Germack et al., 2004) in different models and species.  
The infarct-sparing effect of postconditioning was abolished in the isolated rabbit 
heart model when non-selective A1 receptor inhibitor, PI3-kinase blocker, 
wortmannin or an antagonist for guanyl cyclase was applied for 20 min starting 5 min 
before reperfusion (Yang et al., 2005). Kin et al showed that postconditioning the 
isolate mouse heart, extended the retention time of intravascular adenosine and 
improved contractile function (Kin et al., 2005). Furthermore, this group used specific 
antagonists to demonstrate the required activation of A2 and A3 receptors but not A1 
receptor mediating a cardioprotective effect following postconditioning in the open 
chest rat heart model (Kin et al., 2005). Cohen and colleagues used a non-selective 
A2b receptor agonist to mimic the postconditioning effect in isolated mouse hearts 
that was inhibited by PKC inhibitor, chelerythrine (Philipp et al., 2006). 
 
4.2. Bradykinin 
Bradykinin is a peptide mediator with vasodilatory properties and synthesized from 
by kinin-kallikrein plasma protein system. Clinically, angiotensin-coverting enzyme 
(ACE) inhibiters are administered to hypertensive patients to increase plasma levels 
of bradykinin which serves to reduce high blood pressure. There are 2 bradykinin 
receptor subtypes, namely B1 and B2 found in cardiomycytes. B2 is constitutively 
expressed while B1 is upregulated by hypoxic stress and inflammatory conditions 
















Exogenous admininistration of bradykinin was shown to induce protection 
comparable to IPC in the anaesthetized open-chest rabbit preparation with coronary 
occlusion (Wall et al., 1994). Inhibition of the B2 receptor with icatibant abolished this 
protective effect. Bradykinin‟s ability to mimic IPC has also been successfully 
reproduced in other animal studies (Feng et al., 2000, Goto et al., 1995, Bugge and 
Ytrehus, 1996, Starkopf et al., 1997, Feng and Rosenkranz, 1999).  
 
4.3. Opioids 
Opium is a poppy seed extract that is derived from the plant, Papaver sominferum 
and contains alkaloid compounds such as morphine that is used therapeutically for 
its analgesic and pain alleviation properties. The term „opioids‟ refer to drugs whose 
actions are similar to morphine (but may be chemically different) and includes 
morphine receptor ant- and agonists that act on the opioid system. In the 
myocardium, there are opioid peptides including met-enkephalins, leu-enkephalins 
and dynorphins and three major opioid receptors (µ-, δ-, and κ- subtypes).  
Similar to adenosine, opioid levels were also found to be increased after ischaemia 
(Oldroyd et al., 1992, Paradis et al., 1992, Falcone et al., 1993, Maslov and 
Lishmanov, 1995). Schultz and colleagues administered morphine (non-selective 
agonist) as an IPC mimetic and were able to confer protection in the in vivo rat 
myocardium (Schultz et al., 1995). This effect was removed in the presence of 
glibenclamide, implicating the involvement of the mitoKATP channel. Agonists for δ- 
and κ-, but not µ-opioid receptors have also been able to induce protection (Schultz 
et al., 1997, Schultz et al., 1996, Wang et al., 2001a). This is probably due to the 
abundance of δ- and κ-opioid receptors found in the ventricles of several species 
(Ventura et al., 1989, Xia et al., 1996). The µ-opioid receptor has, however,  been 
detected in the atrial trabeculae (Bell et al., 2000).  
 
4.4. Sphingosine-1-phosphate 
Sphingolipids are an important source for signalling molecules (Merrill et al., 1997). 
They are bioactive metabolites that are involved in many cellular processes such as 
















Spiegel, 1999, Spiegel and Milstien, 2002, Van Brocklyn et al., 1998). Sphingomyelin 
is a major membrane sphingolipid that is hydrolyzed by sphingomyelinases to 
ceramide (Figure 7). Ceramide is then metabolized by ceramidases to sphingosine 
(Baumruker and Prieschl, 2002). Both ceramide and sphingosine are implicated in 
apoptosis. However, sphingosine can be phosphorylated by sphingosine kinases 
(SPK) to form sphingosine-1-phosphate (S1P) (Merrill et al., 1997, Hannun, 1994, 
Kee et al., 2005). 
 
Fig 7. The Sphingolipid metabolic pathway. Sphingomyelin is broken down by hydrolysis into 
ceramide. Ceramide may be phosphorylated to ceramide-1-phosphate or alternatively converted to 
sphingosine by ceramidase. Phosphorylation of sphingosine by sphingosine kinase generates 
sphingosine-1-phosphate. All these reactions can be reversibly metabolized except for the breakdown 
of sphingosine 1-phosphate to hexadecanol and phosphoethanolamine by S1P lyase. LPP, lipid 
phosphate phosphatase; S1P, sphingosine-1-phosphate. (see review, (Melendez, 2008)) 
S1P is a ligand for specific G-coupled protein receptors. There are five known 
















signalling pathways that promote cell survival (Zhang et al., 2007a, Means et al., 
2008, Mazurais et al., 2002, Alewijnse et al., 2004). S1P treated adult mouse 
ventricular cardiomyocytes were protected from hypoxia (Zhang et al., 2007a). A 
S1PR1 specific antibody was used to implicate the critical involvement of this 
receptor (Graeler et al., 2003). Pharmacological inhibition studies suggested that 
S1PR1 and S1PR3 were capable of mediating this protective response (Zhang et al., 
2007a). The PI3-K/Akt pathway and GSK-3β were also shown to be involved 
following inhibition with wortmannin or inactivation by phosphorylation with S1P, 
respectively. Exogenous S1P protected the intact heart against global ischaemia 
reperfusion injury by improving cardiac function recovery (Lecour et al., 2002). 
Ischaemic preconditioning required the activation of SPK1 to reduce infact size (Jin 
et al., 2007) which was lost in PKCε-/- mice (Jin et al., 2004). Preconditioning with 
ganglioside GM-1 (known activator of the prosurvival kinase PKCε) stimulated the 
activity of sphingosine kinase to produce S1P (Jin et al., 2002). This study proved 
that intracellular S1P was dependant on PKCε to induce protection (PKCε-/- mice 
were used) compared to exogenous S1P which was cardioprotective independently 
of PKCε.  
In our laboratory we have shown that S1P preconditioning is abrogated in the 
cardiac specific STAT-3 knockout mice (see Figure 8, unpublished results that I have 
performed during my PhD). Lecour et al. have previously associated TNFα induced 
preconditioning with sphingolipid signalling (Lecour et al., 2002). This would suggest 



















Fig 8. S1P induced preconditioning is dependent on STAT-3. Wildtype hearts subjected to 30min 
of ischaemia and 45min reperfusion exhibited an infarct size of 32.4±2.3%. However, preconditioning 
with S1P (10 nM) significantly attenuated infarct size (12.8±1.2%, p<0.05 vs wildtype control). This 
effect was abolished in cardiac specific STAT-3 deficient mice (30.2±2.8% for control vs 34.5±4.0% 
for S1P, p=ns). IC, ischaemic control; S1P, sphingosine 1-phosphate; STAT-3, Signal Transducer and 
Activator of Transcription-3. 
High density lipoproteins (HDL) are a class of lipoproteins that carry cholesterol from 
the body‟s tissues to the liver. Elevating its levels with statins, fibrates and other lipid-
lowering drugs are used to treat patients with coronary artery disease (Brown et al., 
2006, Otvos et al., 2006, 1984). Recently, S1P has been identified as a constituent 
of HDL and suggested to be responsible for mediating some of its protective effects 
(Theilmeier et al., 2006, Kimura et al., 2001, Okajima, 2002, Frias et al., 2009, Frias 
et al., 2010). Levkau and colleagues demonstrated that HDL and S1P protected the 
in vivo mouse myocardium from ischaemia/ reperfusion injury via a nitric oxide and 
S1PR3 dependant pathway (Theilmeier et al., 2006). Frias et al showed native and 
reconstituted HDL with a varied composition of S1P protected cardiomyocytes 
against doxorubicin induced apoptosis via S1PR2 but not S1PR1 and S1PR3 (Frias 
et al., 2010).  
 
4.5. Ethanolamine 
Ethanolamine (Etn) is a biogenic amine that is stored as membrane lipid, 
phosphatidylethanolamine. It may be formed by the metabolism of the sphingolipid 
pathway or endogenous cannabinoid, anandamide. Since cardioprotective 
















ethanolamine, we explored its preconditioning potential in our laboratory (Kelly et al., 
2010). Pre-treatment with Etn successfully reduced infarct size in the in vivo rat and 
isolated wildtype mouse heart model. This infarct limiting effect was abolished in 
cardiac specific STAT-3 knockout mice (Figure 9, results that I have obtained during 
my PhD). This was the first study, to our knowledge, to suggest a novel 
cardioprotective role for Etn against ischaemia/ reperfusion injury. 
 
Fig 9. Preconditioning with ethanolamine is abrogated in cardiac specific STAT-3
-/-
 mice.  
Pretreatment with ethanolamine (0.3 mM) significantly reduced infarct size compared to the ischaemic 
control in wildtype mice (32.7±2.7% for control vs 15.0±2.7% for ETN, p<0.05). In contrast, 
ethanolamine failed to produce the infarct sparing effect in cardiac specific STAT-3 deficient mice 
(30.2±2.8% in control vs 29.3±2.6%, p=ns). IC, ischaemic control; ETN, ethanolamine; STAT-3, 
Signal Transducer and Activator of Transcription-3. 
 
4.6. Resveratrol 
Resveratrol (3, 5, 4′-trihydroxy-trans-stilbene) is a naturally occurring plant 
polyphenol found in grapes, red wine and peanuts and is touted as having powerful 
antioxidant, anti-atherogenic and anticancer capabilities (see review, (Juhasz et al., 
2010)). Pretreatment with resveratrol was protective against myocardial ischaemia 
reperfusion injury following infarct size reduction and improved postischaemic 
ventricular function in rats fed with the alcohol extract (Sato et al., 2002). A study in 
tumour cells implicated STAT-3 as a target for resveratrol (Yu et al., 2008) led us to 
















resveratrol pretreated mice (Figure 10), (Lamont et al., 2011), (I have performed 
these experiments during my PhD). 
 
 
Fig 10. STAT-3 is essential for resveratrol induced preconditioning. Following 30min ischaemia 
and 45min reperfusion, there was an significantly improved infarct size observed in the resveratrol 
pretreated hearts compared to the wildtype control (42.7±2.5% in control vs 13.1±3.1%, p<0.05). This 
beneficial effect was not observed in cardiac specific STAT-3 deficient mice (41.0±2.0% in control vs 
47.0±2.8%, p=ns). IC, ischaemic control; RVT, resveratrol; STAT-3, Signal Transducer and Activator 
of Transcription-3. 
 
Recently, resveratrol has been shown to activate Silent Information Regulator-1 
(SIRT1), a member of the sirtuin family of class III histone deactylases (Haigis and 
Sinclair, 2010). SIRT1 has been shown to inhibit apoptosis, protect against oxidative 
stress in cardiac myocytes and delay the progression of aging in the mouse heart 
(Alcendor et al., 2004, Alcendor et al., 2007). Transgenic mice with cardiac specific 
overexpression of SIRT1 were protected against myocardial ischaemia/ reperfusion 
injury which involved the transcription factor, FoxO1 and upregulation of prosurvival 
molecules, manganese superoxide dismutase, thioredoxin-1 and Bcl-xL (Hsu et al., 
2010). It is possible that resveratrol may induce its cytoprotective effects via both, 
















5.0. The SAFE pathway and conditioning 
Recently, a novel prosurvival pathway known as Survivor Activating Factor 
Enhancement (SAFE) pathway has been identified (Lecour, 2009). It consists of 
tumour necrosis factor alpha (TNFα) and the Janus Kinase/ Signal Transducer and 
Activator of Transcription-3 (JAK/ STAT-3) pathway.  
5.1 Tumour Necrosis Factor alpha (TNFα) and conditioning 
Tumour necrosis factor alpha (TNFα) is a pleiotrophic cytokine that is present in low 
concentrations in the endothelium and mast cells of healthy hearts (Schulz, 2008). 
Two types of TNF receptors have been characterised, namely TNF receptor 1 
(TNFR1, or p55) and TNF receptor 2 (TNFR2, p75) (Baxter et al., 1999).  These 
receptors are expressed in most cardiac cells, including cardiomyocytes (Kadokami 
et al., 2000). 
Dorge et al. showed that an increased release of TNFα from cardiac cells following 
persistant ischaemia caused contractile dysfunction (Dorge et al., 2002). In the 
setting of myocardial ischaemia reperfusion injury, TNFα can cause irreversible 
injury.  Inhibition with TNFα antibodies in dogs and rabbits or blockade of the TNFR1 
with soluble TNFR1 given during the pre-ischaemic period reduced infarct size 
(Belosjorow et al., 2003, Gu et al., 2006, Sugano et al., 2004). Conflicting data has 
been presented regarding the absolute abolishment of TNFα. One study showed that 
the infarct size was reduced in TNFα knockout mice compared to the wildtype 
(Maekawa et al., 2002) but this was refuted in three separate studies (Labruto et al., 
2005, Dawn et al., 2004, Flaherty et al., 2008). This suggested that the presence of 
TNFα may still be required to elicit a protective response. TNR1 and TNFR2 
knockout mouse models (TNFR1-/- and TNFR2-/-, respectively) were engineered to 
evaluate the role of each receptor in myocardial ischaemia reperfusion injury 
(Flaherty et al., 2008). Abrogation of TNFR1 (TNFR2, still present) reduced the 
infarct size after coronary occlusion compared to wildtype and TNFR1-/- mice. This 
suggested that only TNFR2 was required for protection in this setting. 
TNFα knockout mice failed to induce the infarct sparing effect of ischaemic 
preconditioning (Smith et al., 2002, Ichikawa et al., 2004, Labruto et al., 2005). 
Although, increased levels of pre-ischaemic TNFα has been observed following 
















during the ischaemia-reperfusion injury phase (Belosjorow et al., 1999, Kimura et al., 
2006). Exogenous TNFα added and washed out prior to the sustained ishaemic 
period induced a cardioprotective effect similar to that observed in ischaemic 
preconditioning (Lecour et al., 2005b). Importantly, protection was restricted to low 
dose of TNFα (0.5 ng/ml), as higher doses proved to be detrimental. This 
preconditioning-like protection was also abolished by ROS scavengers (Lecour et al., 
2005a) and inhibition of the mitoKATP channel (Lecour et al., 2002). In the 
myocardium, mitochondria are responsible for the production of ROS during 
ischaemia (Di Lisa et al., 2007). The mechanism of activation of ROS by TNFα is 
unknown but may be present in the mitochondria (Lacerda et al., 2010).The role of 
TNFα in cardioprotection was further explored when addition of the cytokine to 
isolated mitochondria, at the protective concentration, improved respiratory 
parameters following an anoxia-reoxygenation insult (Lacerda et al., 2010). The 
observed decrease in inner mitochondrial membrane potential was removed in the 
presense of the mPTP inhibitor, cyclosporine A, therefore suggesting that TNFα may 
mediate its protective effect via the transient opening of the mPTP.  
 
5.2. Signal Transducer and Activator of Transcription-3 (STAT-3) pathway and 
conditioning 
5.2.1. Activation of STAT-3 
The Janus kinases (JAKs) are a family of nonreceptor tyrosine kinases that are 
located in the cytosol and associate with membrane receptors to initiate signal 
transduction from the cell to the nucleus (Imada and Leonard, 2000). Structurally, 
JAKs are composed of seven highly conserved JAK homology domains (JH). They 
possess a JH1 domain (kinase domain) which is responsible for the catalytic activity 
of the JAKs; a JH2 domain (pseudo-kinase domain) that is suggested to serve as a 
docking site for the STATs (Imada and Leonard, 2000); JH3-JH4 region, with a Src 
Homology 2 (SH2)-like domain but does not have phosphotyrosine binding ability; 
and the JH4-7 region, which have a FERM domain (four-point-one, ezrin, radixin, 
moesin) and is involved in JAK-receptor interactions (Figure 11). There are four 
known JAKs in mammals (JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2)) 
















myocytes (Kurdi and Booz, 2007). All of the seven STAT forms are expressed in the 
heart, i.e. STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. 
However, STAT1 and STAT3 are the most studied.  
 
Fig 11. Structure of JAK1 and JAK2 domains. JAK, Janus kinase; JH, JAK homology; FERM, Four-
point-one, Ezrin, Radixin, Moesin domain; SH2, Src homology. (from review, (Kurdi and Booz, 2007)) 
Activation of STAT-1, in association with pro-apoptotic factors such as caspase-1 
and p53, is involved in cardiac myocyte induced apoptosis following IR injury 
(Stephanou et al., 2000b, Stephanou et al., 2001). In contrast, STAT-3 activates anti-
apoptotic genes such as Bcl-2 and Bcl-xL (Stephanou et al., 2000a). For the purpose 
of this thesis, only STAT-3 will be further discussed. The structure of the STAT 
proteins is conserved within the coiled-coiled domain, DNA binding domain, linker 
domain and SH2 domain. The transcriptional transactivation domain (TAD) is highly 
conserved at the carboxyl terminus. The amino terminus is less conserved between 
the STATs and it may be involved in specific protein responses (Figure 12).  
 
Fig 12. Structure of STAT-3 domain. Refer to text for details. (from review, (Stephanou, 2004)) 
The JAK2/ STAT-3 pathway may be triggered by the binding of a ligand to a 
transmembrane receptor leading to the homo- or heterodimerization of the receptor 
and subsequent phosphorylation and activation of JAK2, associated at the receptor‟s 
















be activated independent of receptor dimerization or association. This has been 
shown for JAK2 activation in ischaemia/ reperfusion and preconditioning studies 
where the initiating response is mediated by oxidative stress or G-protein coupled 
receptors (see review, (Kurdi and Booz, 2009)). JAK2, in turn, phosphorylates the 
receptor which creates docking sites for the SH2 domain of cytosolic STAT-3. STAT-
3 is phosphorylated at its tyrosine-705 residue and forms a homo- or heterodimer by 
interaction with the SH2 domain of another STAT monomer. The dimers moves 
away from the receptor and translocate into the nucleus where they bind specific 
DNA sequences and regulate expression of proteins involved in angiogenesis, 
inflammation, apoptosis, cellular signalling and extracellular matrix composition 
(Hilfiker-Kleiner et al., 2004, Hilfiker-Kleiner et al., 2005, Snyder et al., 2008). STAT-
3 is phosphorylated at its serine-727 residue in its TAD domain which leads to 
transcription. This transcription can be negatively regulated by Protein Inhibiters of 
Activated STAT (PIAS) proteins and positively regulated by p300 / Cyclic AMP 
Response Element Binding (CREB) protein (Wang et al., 2005) and CR-6-interacting 
factor 1 (CRIF1) (Kwon et al., 2008). STAT-3 proteins are dephosphorylated by 
nuclear phosphatases and recycled back to the cytosol. Suppressor of Cytokine 
Signaling (SOCS) genes are also activated by STAT-3 DNA binding and may 
negatively regulate the JAK2/ STAT-3 pathway by binding to JAK, the receptor or 
competing with STAT-3 for docking sites on the receptor (see review, (Cooney, 
2002)). STAT-3 has been recently identified in the mitochondria but its role and 
mechanism of action are unclear (Wegrzyn et al., 2009). Mitochondria isolated from 
STAT-3-/- murine hearts did however, exhibit defects in complexes I and II of the 


















Fig 13. Schematic representation of the JAK/ STAT-3 pathway. Following a stimulus, JAK is 
recruited to the transmembrane receptor where it becomes phosphorylated. Subsquent dimerization 
allows JAK to phosphorylate cytosolic STAT-3 at its tyrosine 705 residue. Phosphorylated STAT-3 
forms homodimers which translocate to the nucleus where it upregulates transcription and is 
additionally phosphorylated at its serine 727 residue to enhance DNA interaction. STAT-3 has also 
been identified in the mitochondria but its role is currently unclear. JAK, Janus kinase; ser, serine; Tyr, 
tyrosine; STAT-3, Signal Transducer and Activator of Transcription-3. 
 
5.2.2. STAT-3 in the heart 
The heart is the first organ to form during embryonic development (Foshay et al., 
2005). STAT-3 has been shown to be critically important during this phase of life as 
its genetic ablation led to embryonic lethality (Takeda et al., 1997). However, 
















Mendelian inheritance ratio and survive to adulthood. They do not exhibit any signs 
of cardiac dysfunction until 3 months of age where in contrast to the wildtype, they 
possess reduced capillaries and mild levels of interstitial fibrosis (Jacoby et al., 2003, 
Hilfiker-Kleiner et al., 2004). However, STAT-3-/- mice become susceptible to heart 
failure as they progressively age, with increased apoptosis and increased cardiac 
fibrosis. 
 
5.2.3. STAT-3 in ischaemia/ reperfusion injury 
The JAK/STAT-3 pathway was activated via glycoprotein (gp) 130, a signal-
transducing membrane receptor in cardiac myocytes following exposure to cytokine, 
Leukemia Inhibitory Factor (LIF) (Kunisada et al., 1996). The cardiac specific 
overexpression of STAT-3 was protective against doxorubicin induced 
cardiomyopathy (Kunisada et al., 2000). Both LIF and an adenovirus-mediated 
transfection of constitutively activated STAT-3 protected rat neonatal cardiomyocytes 
against hypoxia/ reoxygenation induced oxidative stress through the upregulation of 
MnSOD (Negoro et al., 2001). Cardiotrophin-1, another cytokine, also enhanced cell 
survival and reduced apoptotic cell death in cultured cardiac myocytes by activation 
of STAT-3 (Stephanou et al., 1998). Furthermore, STAT-3 deficient mice were found 
to be more susceptible to ischaemic injury and developing heart failure (Hilfiker-
Kleiner et al., 2004, Jacoby et al., 2003). These studies suggested an important role 
for STAT-3 in cardiac survival. 
Negoro et al were the first to show the cytoprotective activation of the JAK/ STAT-3 
pathway in a rat acute myocardial infarction (AMI). Pretreatment with a JAK2 
inhibitor, AG490 before left descending coronary ligation, increased caspase-3 and 
Bax mediated apoptosis and suppressed the phosphorylation of STAT-3 (Negoro et 
al., 2000). Cardiac specific mice expressing constitutively activated STAT-3 exhibited 
significantly reduced infarct size compared to non-transgenic mice and ROS 
scavengers, metallothionein1 and metallothionein2 were upregulated in the 
transgenic mice (Oshima et al., 2005). Genetic deletion of these scavengers 

















5.2.4. STAT-3 and preconditioning 
Bolli and colleagues demonstrated activation and cytosolic to nuclear translocation of 
STAT-3 in the in vivo delayed preconditioning of the mouse myocardium (Xuan et al., 
2001).  Pretreatment with JAK2/ STAT-3 inhibitor, AG490 abolished this protective 
effect and the upregulation of inducible nitric oxide synthase (iNOS). Hattori et al. 
showed the activation of JAK2 and STAT-3 in early ischaemic preconditioning in the 
isolated rat working heart model (Hattori et al., 2001). IPC also induced the 
recruitment of iNOS and reduced apoptotic cell death with the upregulation of anti-
apoptotic gene, bcl-2 and downregulation of proapoptotic gene, bax. Furthermore, 
the protective effects of classical IPC were not observed in cardiac-specific deficient 
STAT-3 mice (Smith et al., 2004).  
In addition to the pharmacological preconditioning mimetics described earlier, 
cardiotrophin-1 (Brar et al., 2001), erythropoietin (Rafiee et al., 2005, Nishihara et al., 
2006) and cannabinoid agonists (Montecucco et al., 2009) have also been implicated 
to mediate cardioprotection via activation of STAT-3. Lecour et al demonstrated a 
critical role for STAT-3 in TNFα induced preconditioning where proapoptotic factor, 
Bad was inactivated by phosphorylation (Lecour et al., 2005b). Transferrence of 
cardioprotection was shown by the treatment of isolated rat hearts with coronary 
effluent from preconditioned rat hearts resulted in activation of the JAK/STAT-3 
pathway (Huffman et al., 2008) that was abolished with AG490. Opioid induced 
cardioprotection was also abolished with AG490 and reduced the phosphorylation of 
GSK-3β, suggesting that STAT-3 may indirectly exert its protective effects on the 
mitochondria by GSK-3β mediated inhibition of the mPTP (Gross et al., 2006).  
At the time, I started researching my thesis, the role of STAT-3 in ischaemic and 
pharmacologically postconditioning was unknown and remained to be determined.  
 
6.0. Forkhead box subfamily O (FOXO) 
6.1. Definition 
The Forkhead helix family of transcription factors are characterized by a conserved 
DNA binding domain and are critical for early development and adult physiology 
















development such as FOXC1, FOXC2, FOXH1, FOXM1, FOXO-1 and FOXP1. 
FOXO-1, FOXO-3 and FOXO-4 are essential for cardiac function and involved in 
roles such as response to oxidative stress, regulation of metabolism and apoptosis 
(Papanicolaou et al., 2008, Kops et al., 2002, Puigserver et al., 2003, Stahl et al., 
2002).  
 
6.2 FOXO in the heart 
FOXO-1 and FOXO-3a are the most dominant isoforms located in the heart. The 
nuclear localization sequence of FOXO may be phosphorylated by Akt (Brownawell 
et al., 2001, Brunet et al., 2002). The phosphorylated FoxO interacts with a subset of 
14-3-3 proteins localized in the nucleus, causing translocation of the FOXO-14-3-3 
complex to the cytoplasm via the nuclear export protein Crm1. FOXO becomes 
sequestered by 14-3-3 proteins and is rendered inactive in the cytosol (Brunet et al., 
1999, Biggs et al., 1999). Mutation of the Akt phosphorylation sites on FOXO 
proteins resulted in only FOXO nuclear localization and insusceptibility to Akt-
mediated inhibition (Takaishi et al., 1999). The PI3K-Akt signaling is a major 
regulator of FOXO activity. 
Insulin and insulin-like growth factor-1 have the ability to activate Akt and thereby 
inactivating FOXO by phosphorylation (Matsuzaki et al., 2003). However, sustained 
FOXO activation by infecting cardiac myocytes with a FOXO-1 adenovirus, created a 
reverse feedback via increasing Akt levels and subsequently rendering 
cardiomyocytes insensitivite to insulin (Ni et al., 2007). The exact pathophysiological 
role of FOXO still requires further investigations. 
 
6.3 FOXO and conditioning 
The involvement of FOXO in preconditioning has only been described directly as a 
downstream target of Silent information regulator 1 (Sirt1). Sirt1 belongs to the sirtuin 
family class III histone deacetylases and thus require NAD+ for their enzymatic 
activity (Imai et al., 2000). Sirt1 are involved in activities such as retarding aging and 
protecting the heart against oxidative stress (Alcendor et al., 2004, Alcendor et al., 
















grapes, activated Sirt1 and phosphorylated FOXO-1 in the heart (Mukherjee et al., 
2009). This resulted in a decreased infarct size and reduced apoptosis when isolated 
hearts were subjected to ischaemic injury. Sirt1 was also shown to inhibit oxidative 
stress by upregulation of mnSOD via FOXO-1 during ischaemia reperfusion (Hsu et 




































































Ischaemic postconditioning is a phenomenon whereby brief episodes of intermittent 
ischaemia and reperfusion applied immediately following a prolonged ischaemic 
event significantly reduces infarct size and improves cardiac function. This profound 
effect has been translated across different species although the exact signalling 
mechanism has yet to be determined, as this may yield novel therapeutic 
opportunities against ischaemic heart disease. In preconditioning, two prosurvival 
paths have been identified. The first was the Reperfusion Injury Salvage Kinase 
(RISK) pathway which involved the activation of prosurvival kinases, 
phosphatidylinositol 3-kinase (PI3-Kinase)/ Akt and extracellular signal-regulated 
kinase (ERK 1/2) which has been well established and documented in 
cardioprotective studies. More recently, the Survival Activating Factor Enhancement 
pathway has been discovered that involved the activation of Tumour Necrosis 
Factor-alpha (TNFα) and Signal Transducer and Activator of Transcription-3 (STAT-
3).  
Pharmacological studies with preconditioning agents such as adenosine, bradykinin, 
opioids and sphingosine 1-phosphate (S1P) have been shown to successfully confer 
protection and implicate some of these and downstream factors. Postconditioning, 
however, is a relatively new discovery. The prosurvival kinases of the RISK pathway 
and the mitochondria have been implicated but very little is known about the 
involvement of the SAFE pathway. STAT-3 is a transcription factor that is associated 
with cell growth, proliferation and survival. The aim of this present study was to 
investigate the role of STAT-3 in relation to the SAFE pathway in ischaemic and 
pharmacological postconditioning induced cardioprotection. 
 
1.1 Hypothesis and Objectives 
We hypothesized that activation of STAT-3, as part of the SAFE pathway, is 
essential in both ischaemic and pharmacological postconditioning to confer 



















Fig 14. Schematic representation of hypothesis and objectives in ischaemic and 
pharmacological postconditioning. The JAK/STAT-3 pathway may be stimulated by ischaemic or 

























To fulfil this aim, we set the following objectives: 
1) To investigate the role of STAT-3 in ischaemic postconditioning 
To achieve this objective we will employ the use of cardiac specific STAT-3 deficient 
(STAT-3-/-) mice and their respective wildtype. Isolated wildtype hearts will be 
postconditioned to optimise the parameters suited for this model. STAT-3-/- hearts 
will be subjected ot ischaemic postconditioning. Should STAT-3 prove necessary in 
IPostC induced cardioprotection, we will use the western blot technique to confirm its 
role and examine GSK-3β as a possible downstream target of STAT-3. 
2) To investigate the role of STAT-3 with classic pharmacological postconditioning 
agents 
For this study, we will use TNF deficient mice (TNFα-/-), and cardiac specific STAT-3 
deficient mice and their respective wildtypes. Isolated hearts will be subjected to an 
ischaemia reperfusion insult and classic pharmacological agents, adenosine, 
bradykinin and opioids will be used to mimic the postconditioning effect.  
3) To investigate the role of STAT-3 in HDL/ S1P induced cardioprotection and to 
delineate a possible interplay between the SAFE and RISK pathways to protect the 
heart   
To achieve this objective we will use TNF deficient (TNFα-/-), cardiac specific STAT-3 
deficient (STAT-3-/-) mice and their respective wildtypes. HDL will be extracted from 
the blood of healthy patients. Isolated hearts will be subjected to an ischaemia 
reperfusion insult and perfused with either HDL or S1P to confer a protective effect 
similar to postconditioning. Should STAT-3 prove necessary, we will examine the 
possible interplay between the SAFE and RISK pathways by using inhibitors of 
various pathways and the western blot technique to evaluate Akt, ERK1/2, STAT-3 




























































1.0. Genetically modified animals 
All the animal experiments conducted with approved by the Animal Research Ethics 
Committee of the University of Cape Town, and followed the recommendations 
stipulated in the Guide for the Care and Use of Laboratory Animals published by the 
US National Institute of Health (NIH Publication No.85 (23), revised 1996). 
 
1.1. Mouse models to investigate the role of STAT-3 in cardiac protection 
Homozygous TNFα-deficient (TNFα-/-) mice and their respective wildtype, Black 6 x 
129S (TNF-WT) were a generous gift from Dr Muazzam Jacobs and Professor 
Bernhard Ryffell, Department of Immunology, University of Cape Town. 
Cardiomyocyte specific STAT-3- deficient (STAT-3-/-) mice and their respective 
wildtype, were based on a C57 Black 6 background and created in our facilities by 
crossing homozygous floxed STAT-3 mice with heterozygous MLC2V-driven Cre 
recombinase mice, as previously described (Smith et al., 2004). All mice were 14-16 
weeks of age, unless where indicated otherwise. 
 
1.1.1. Creation of cardiomyocyte specific STAT-3 deficient mice 
Early attempts to create a whole body STAT-3 deficient mouse were unsuccessful as 
it resulted in the degeneration of mouse embryos between days 6.5 and 7.5 of 
gestation (Takeda et al., 1997). This indicated the STAT-3 was expressed early in 
life and critical for the embryonic development. For the purposes of our 
investigations, we undertook the creation of a conditional, cardiac specific STAT-3 
knockout mouse. This was achieved with the Cre-Lox P system of conditional gene 
ablation. 
1.1.2. Cre Lox P technology 
This system of conditional gene targeting employed two separate transgenic gene 
lines; a homozygous STAT-3 floxed mouse (STAT-3F/F; F-Floxed) and an organ 
specific heterozygous Cre recombinase-expressing mouse (CreT/N; T – Transgene 
and N – Normal). These 2 strains of mice were then crossed to produce the organ 
















1.1.3. STAT-3 floxed mouse 
Floxed mice are animals that have a specific DNA sequence, Lox P (Locus of X-ing 
over P) site inserted and integrated into their germ line. Two Lox P sites have been 
inserted in the DNA sequence of the protein to be disrupted such that the target 
segment is flanked by each Lox P fragment. Each Lox P site contains two 13 base 
pair repeats separated by an 8 base pair asymmetric spacer region (Figure 15). Lox 
P sites arranged in an opposite orientation to each other, invert the DNA between 
them (Figure 16A). In contrast, Lox P sites arranged in a direct orientation act as 
targets for excision of the DNA between them (Figure 16B). Heterozygous mice 
possessing Lox P sites integrated into the STAT-3 germ line (CreN/N STAT-3F/N) in a 
direct orientation (Figure 16B) were obtained from Professor S Akira, Osaka 
University, Japan (Takeda et al., 1997). 
 
Fig 15. Lox P site. DNA sequence of a Lox P site which is made up of 2, 13 base pair inverted 
repeats separated by an 8 base pair asymmetric spacer region. DNA, Deoxyribonucleic Acid.   
 
Fig 16. Functional orientation of Lox P sites. The orientation in which Lox P sites are integrated 
into the genome determines whether the DNA is inverted as in (A) or excised as in (B). DNA, 
















1.1.4. Cardiac specific expressing Cre Recombinase mouse 
The cardiac specific Cre recombinase expressing mouse used to generate our 
STAT-3 Knockout animal was a generous gift from Professor Kenneth R Chien of 
Harvard Medical School. The DNA between the Lox P sites is excised by the 
expression of the 38 kDa bacteriophage P1 Cre recombinase protein (Chien, 2001). 
This enzyme cleaves the sequence, removing the DNA and leaving behind one Lox 
P site (Figure 17C). The expression of the Cre enzyme was placed under the control 
of a tissue specific promoter for cardiomyocytes. This ensured that the Cre 
recombinase would only be expressed in the cardiac tissue and thus specifically 
target deletion of the floxed sequence. A promoter with a high transcriptional activity 
had to be chosen that would result in a prominent expression of the Cre 
recombinase protein and lead to a high rate of Lox P site excision. To this end, the 
Myosin Light Chain 2 Ventricle (MLC2V) promoter was selected (Chen et al., 1998). 
The Cre recombinase was placed on one of the alleles (allele – one of 2 forms of the 
same gene), under control of the MLC2V promoter. This promoter is only active in 
the ventricles of adult mice and is highly expressed ensuring an elevated expression 
of Cre recombinase.  
Lox P sites were introduced into introns 21 and 22 (non-coding regions of DNA) 
which flanked the tyrosine phosphorylation site of exon 21 (coding region of DNA) 
(Figure 17B). Removal of exon 21 (Figure 17B) by Cre recombinase will resulted in 


















Fig 17. Targeted deletion of STAT-3. Gene organisation in STAT 3 
F/F 
mice before and after Cre 
mediated disruption. (     ) Exon 21 of STAT 3 was flanked by identical lox P (     ) sites (B). Each site 
is a target for Cre recombinase which is used to disrupt the STAT 3 gene, effectively knocking STAT 
3 out. “a” and “b” are the primers used to determine whether the mouse is harboring a floxed STAT 3 




















1.1.5. Breeding strategy for the establishment of a cardiac specific STAT-3 
deficient mouse colony 
The cardiac specific STAT-3 knockout with littermate controls were bred according to 
Figure 18. The original pairs of STAT-3 floxed mice had no Cre insert and were 
heterozygous for the STAT-3 floxed allele (CreN/N STAT-3F/N). These mice were bred 
together and the genotypes generated were calculated as in the Punnett square of 
Figure 19A and the subsequent genetic distribution of genotypes in Figure 19B. The 
CreN/N STAT-3F/F mice were selected for establishing a stable breeding colony. 
 
The CreN/N STAT-3F/F mice were crossed with the transgenic Cre recombinase 
expressing strain (CreT/N STAT-3N/N) to generate CreT/N STAT-3F/N mice (Figure 20A).  
Cross breeding these mice gave us two distinct genotypes, CreT/N STAT-3F/N and 
CreN/N STAT-3F/N mice (Figure 20A) in a 50/50 ratio (Figure 20B). From this result, 
CreT/NSTAT-3F/N mice were selected and crossed with CreN/N STAT-3F/F mice (Figure 
19B and Figure 21) to spawn CreT/N STAT-3F/F mice, the desired genotype of cardiac 
specific STAT-3-/- mice. This breeding approach lso gave rise to three other distinct 
genetic backgrounds (Figure 21A) with the STAT-3-/- mice making up a quarter 


















Fig 18. Generation of ventricle specific knockout mice. N, normal; T, Transgenic Cre insert; F, 
Floxed STAT-3. Of note is that Cre
T/T 
is embryo lethal due to the absence of MLC2V. Here no 































. The punnett square (A) is used to 
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) mice. The resulting Mendelian ratios of the offspring is shown in B. Abbreviations 
are as in text.  
 
 







































































 were discarded as they did not possess the correct genetic configuration for both 
wild-type or STAT-3 KO mice. Abbreviations are as in text. 
 
CreT/N STAT-3F/F mice were selected and used to create and maintain a stable 
breeding population of STAT-3-/- and littermate control mice (Figure 22A). The 
Mendelian STAT-3-/- to wild-type ratio of this breeding strategy produced 25% wild-
type (CreN/N STAT-3F/F) and 50% STAT-3-/- (CreT/N STAT-3F/F) mice (Figure 22B). In 
addition, 25% of the embryos were hom zygous for the Cre insert, i.e., CreT/T STAT-
3F/F which was embryo lethal, as both alleles of the MLC-2V gene were replaced, 
and effectively deleted this critical gene (Chen et al., 1998).  
 








. The breeding strategy used to 
maintain a stable mouse colony is illustrated in (A). The offspring ratio is shown in (B). Abbreviations 

















Since the mice were phenotypically similar, genotyping was employed to differentiate 
the TNFα-/- and STAT-3-/- from their respective wildtype. Genomic DNA was 
extracted from mouse tail cuts sourced at weaning (3 weeks of age). Genotyping 
was carried out by means of polymerase chain reaction (PCR). 
 
1.2.1. DNA Extraction 
Approximately 1 cm of mouse tail was excised and digested overnight at 55°C in 400 
µl tail digestion buffer (0.5 M Tris pH 8.0, 0.1 M EDTA, 1% SDS) with 1 mg/ml 
proteinase K (Roche, Mannheim) in 1.5 ml micro-centrifuge tubes. Each tube 
containing digested sample was then treated with 400 µl of 
Phenol:Chloroform:Alcohol (25:24:1) (Sigma,USA) mixture and gently inverted to 
mix. Samples were centrifuged at 13,500 rpm (Heraeus MK202, Germany) for 10 
minutes at room temperature to remove the cellular debris by density separation. 
The bottom layer containing the debris was carefully removed and discarded with a 
sterile barrier tipped pipette. Phenol traces were removed from the DNA with the 
addition of 200 µl of chloroform (Sigma, USA) to each tube and gentle inversion prior 
to centrifugation at 13,500 rpm for 5 minutes. Two layers are formed in each tube, 
isolating the DNA into the top layer. Once again, the bottom layer is gently discarded 
with aid of sterile barrier tips. The tubes containing the top phase were centrifuged at 
13,000 rpm for 10 minutes, pelleting any remaining debris. After transferring the 
liquid phase into a new sterile 1.5 ml micro-centrifuge tube, 50 µl of 7.5 M 
ammonium acetate (Merck) and 1ml 100% ethanol was added to each tube and 
gently inverted to mix. DNA was visible at this point, as a white stringy precipitate. 
The DNA solution was transferred to another clean micro-centrifuge tube containing 
500 µl of 70 % ethanol to hydrate the DNA and centrifuged at 13,000 rpm for 10 
minutes. The ethanol was carefully decanted taking care not to discard DNA settled 
at the base of the tube. DNA was air dried to evaporate the remaining ethanol and 
then dissolved in 50-75 µl of ultra pure RNAse free water. Samples were stored at -

















1.2.2. Polymerase Chain Reaction (PCR) 
TNFα-/- mice were generated by the insertion of a phosphoglycerate kinase-
neomycin expression cassette within the TNFα gene. This technique of targeted 
gene deletion and detection has been previously described (Marino et al., 1997). 
Genotyping of the TNFα gene was randomized to confirm the genotyping 
characteristics of the mice. In contrast, cardiac specific STAT-3 deficient mice were 
genotyped at each stage of the breeding process since the offspring could be both 
STAT-3-/- and wildtype. Hence, candidate STAT-3-/- mice were screened for the 
presence of Cre recombinase insertion and floxed alleles. 
 
1.2.3. Sequences and PCR for TNFα-/- 
a) TNF-/-: Sense primer:  5‟-CTA AAT GAA CTG CAG GAC GA-3‟ 
  Anti-sense primer: 5‟-ATA CTT TCT CGG CAG GAG CA-3‟ 
 
Neomycin: Sense primer: 5‟-CTG AAT GAA CTG CAG GAC GA-3‟ 
  Anti-sense primer: 5‟-ATA CTT TCT CGG CAG GAG CA-3‟ 
 
PCR reactions were performed in a volume of 50 ml: 
10x Magnesium free buffer:    10.0  µl 
4 mM MgCl2:        8.0  µl 
100 µM dNTP‟s:      1.6 µl 
Primer (TNF or Neo):     0.5 µl 
β actin 3‟:       0.5 µl 
β actin 5‟:       0.5 µl 
H2O:        26.9 µl 
















DNA sample:       1.5 µl 





























































Fig 25. UV gel analysis revealing the targeted TNF gene deletion from mouse genomic DNA 
 
1.2.4. Sequences and PCR for cardiac specific STAT-3-/- mouse model 
Cre positive mice were identified with the following sequences: 
Cre Sense primer:   5‟-GTT CGC AAG AAC CTG ATG GAC A-3‟ 
Cre Anti-sense primer:  5‟-CTA GAG CCT GTT TTG CAC GTT C-3‟ 
The presence of the Myosin Light Chain Isoform-2 Ventricle (MLC2V) gene was 
included as a positive control as it is exclusively expressed in the heart. 
MLC2V Sense primer:  5‟-GGC AAC CCT CAG ACA CCA T-3‟ 
MLC2V Antisense primer: 5‟-TGT GGA GGC TCT GGA TCA GGA C-3‟ 
 
The PCR reactions were performed in 50 µl volumes as follows: 
10x Magnesium free buffer:    10.0  µl 
4 mM MgCl2:        8.0  µl 
100 µM dNTP‟s:      1.6 µl 
Primer:       0.5 µl 
β actin 3‟:       0.5 µl 
m 
700bp 
1 2 3 4 8 7 6 5 10 9 
Lane 1 = water control 
Lanes 3 and 5 = TNF
-/-
 
Lanes 2, 4, 6-10 = TNF-WT 
















β actin 5‟:       0.5 µl 
H2O:        26.9 µl 
Taq:        0.5 µl 
DNA sample:       1.5 µl   











Floxed STAT-3 gene segments yielded a 250 bp fragment on the gel. A 200 bp 
fragment was observed if STAT-3 gene was not floxed. Heterozygous mice were 
identified by the presence of a double band. STAT-3 floxed and non-floxed DNA 
were amplified with the following primers: 
STAT-3 primer (a)  5‟-CCT GAA CAA GTT CAT CTG TGT GAC-3‟ 
STAT-3 primer (b)  5‟-CAC ACA AGC CAT ACT CTG GTC TCC-3‟ 
 
The PCR reactions were performed in 50 µl volumes as follows: 
10x Magnesium free buffer:    5.0  µl 
4 mM MgCl2:        4.0  µl 

























Primer:       0.25 µl 
β actin 3‟:       0.25 µl 
β actin 5‟:       0.25 µl 
H2O:        13.2 µl 
Taq:        0.25 µl 
DNA sample:       1.0 µl 















Fig 28. UV gel analysis showing Cre positive band (350 bp) and the control MLC2V band at 600 














1 2 3 4 5 6 7 8 9 
lanes 1,3,5 = STAT-3
-/-
 
lanes 2,4,6-8 = STAT-3 WT 
















1.3. Agarose gel Electrophoresis 
The PCR product was separated on a 2% agarose gel. 100 ml of Tris Acetate 
electrophoresis buffer (TAE) (0.04 M Tris-Acetate, 0.001 M EDTA) was added to 2 
grams of agarose (Whitehead Scientific, RSA)and heated in a microwave oven at 70 
% power until dissolved. It was possible to visualize the amplified DNA fragments 
under ultra-violet (UV) by the addition of 1 µl ethidium bromide per 100 ml agarose 
gel. The agarose solution was poured into the gel mould and allowed to set for 15 
minutes. TAE buffer was added to gel apparatus prior to removal of the gel combs. 
Each well was loaded with 10 µl of PCR product and 2 µl of gel lading buffer (0.25% 
Bromophenol Blue-Xylene Cyanole Dye Solution, Sigma). 4 µl of a 100 bp DNA 
ladder marker (Roche, Germany) was also loaded on to the gel and ran concurrently 
with the samples at 90 V for 30 - 40 minutes. The bands were visualized on a 
transluminator (UviTec, USA). Gel photos of the PCR were recorded using the 
UviTec Geldoc apparatus with UVIband software v.97 (Cambridge, UK). 
 
2.0. Isolated mouse heart model 
Adult male TNFα-/- and cardiomyocyte-specific STAT-3-/- mice and their respective 
wildtypes were anaesthetized with an intraperitoneal injection of sodium 
pentobarbital (60 mg/kg) and heparin (25 IU ip).  The pedal reflex test was 
implemented to confirm an adequate level of anaesthesia prior to the opening of the 
chest.  The sternum and attached coastal cartilage was excised to provide access to 
the mediastinum. Hearts were rapidly excised and placed in cold arrest Krebs-
Henseleit solution (NaCl 118.0 mM; NaHCO3 24.0 mM; KCl 4.0 mM; NaH2PO4 1.0 
mM; CaCl2 2.5 mM; MgCl2 1.2 mM; di-sodium EDTA 0.5 mM; glucose 10.0 mM; 
gassed with 95% O2/5%CO2 at 37°C) before mounted on a Langendorff retrograde 
perfusion apparatus.  Pressure was kept constant at 110 cmH2O and temperature 
readings was acquired by means of a fine thermocoupled wire (Physitemp, NJ, 
USA), inserted into the right atrium and monitored on a Digitron 2600T temperature 
sensor (Torquay, UK).  Developed tension was assessed in the hearts by the 
application of a rigid lightweight lexan coupling rod connected to a force placement 
transducer (Grass FT03C, MA, USA).  A 4-0 silk attached to a 20 mm curved 
















the coupling rod.  Diastolic tension was adjusted to a 2 g weight and hearts were 
paced to 560 bpm.  Tension output was recorded on a Powerlab Labchart recorder 
(ADI instruments, Australia).  Coronary flow rate was measured at timed intervals. A 
minimum flow rate of 1.5 ml/min and maximum flow of 5.0 ml/min of coronary flow 
rate, heart rate between 460 - 600 bpm and developed force ≥ 4 was deemed 
acceptable. These parameters (coronary flow, heart rate, and developed force) 
served as a measure of cardiac function. No haemodymanic data was collected. 
Isolated hearts were allowed to stabilize for 25 minutes prior to 35 minutes global 
ischaemia (achieved by means of a stopcock to prevent further flow of buffer into the 
heart from the aortic cannula) and a 45 minute reperfusion period (Smith et al., 
2002). 
 
Fig 29: Mouse heart mounted on Langendorff apparatus. The heart is cannulated through its aorta 
in retrograde perfusion. Pacer electrodes are used to pace the heart to 560 bpm and tension applied 

















2.1. Infarct size assessment 
At the end of the experiment, hearts were removed from the perfusion apparatus and 
stained with triphenyltetrazolium chloride (TTC, 1% in phosphate buffer, pH 7.4) for 1 
minute at 37°C (described previously, (Sumeray et al., 2000)).  Hearts were then 
frozen overnight and sectioned perpendicular to the apex, into 1 mm slices.  The 
slices were tightly placed between two glass plates at a distance of 0.5 mm apart 
and digitally scanned.  Infarct size was then calculated using computerized 
planimetry (Planimetry+, Boreal Software, Norway). The borders of inclusion and 
exclusion were analyzed blindly by another researcher and the same person to 
ensure consistency of results. 
                                          
 
Fig 30. TTC staining for infarct size measurement. TTC reacts with the NADPH in live tissue and 
stains the cells with a brick red colour. The infarcted tissue is lacking in NADPH and remains pale. 
This distinction allows for the determination of infarct size by planimetry. 
 
3.0. Nuclear and cytosolic protein extraction 
This method of protein extraction (adapted from Williams and Ford, 2001, (Williams 
and Ford, 2001)) from mouse heart tissue involved the homogenization of tissue in 
the following lysis buffer:  
Solution A (30 ml)    µl   Final Concentration 
1 M Hepes, pH 7.9   600    20 mM 
2 M MgCl2    37.5    2.5 mM 
500 mM EDTA   6    100 µM 
100 mM β-glycerophosphate 6000    20 mM 
















Triton X-100 (100%)  15    0.5 % 
100 mM DTT    1500    500 µM 
100 mM NaVO4   30    100 µM 
EDTA-free protease inhibitor 1200    - 
100 mM PMSF   300    1 mM 
5 M NaCl    450    75 mM 
dH2O     19862    - 
 
Solution B (10 ml)    µl   Final Concentration 
1 M Hepes, pH 7.9   200    20 mM 
2 M MgCl2    12.5    2.5 mM 
500 mM EDTA   2    100 µM 
100 mM β-glycerophosphate 2000    20 mM 
Triton X-100 (100%)  100    1.0 % 
100 mM DTT    1500    500 µM 
100 mM NaVO4   10    100 µM 
EDTA-free protease inhibitor 400    - 
100 mM PMSF   100    1 mM 
5 M NaCl    150    75 mM 
dH2O     6526    - 
 
Frozen hearts were wrapped in aluminium foil and pulverized under liquid nitrogen 
















Samples were homogenized twice by Polytron at setting 4 for 5 seconds. The 
suspension was then centrifuged at 10000 g (12 000 rpm) for 5 minutes at 4°C. The 
supernatant containing the cytosolic fraction was collected and transferred into a 
fresh tube. The pelleted fraction was resuspended in 300-500 µl of Solution B and 
transferred to a clean micro-centrifuge tube. After centrifugation for 30 minutes at 
10000 g (12 000 rpm) at 4°C, the supernatant containing the nuclear fraction was 
carefully removed in transferred to a clean tube. 
 
3.1. Mitochondrial and cytosolic protein extraction 
This method of mitochondrial and cytosolic protein extraction (adapted from Lewin et 
al., 2008, (Lewin et al., 2008)) from mouse heart tissue involved the homogenization 
of tissue in the following lysis buffer:  
Lysis Buffer      Incubation buffer 
100 mM Tris-HCl, pH 7.4    250 mM Sucrose 
250 mM Sucrose     25 mM Tris 
1 mM Dithiothreitol (DTT)    8.5 mM KH2PO4 
1 mM EDTA 
Low ionic strength sample buffer 
400 µl 10 % Sodium dodecyl sulphate (SDS) 
400 µl glycerol 
40 µl mercaptoethanol 
1.16 ml 5 mM Tris, pH 6.8 
Bromophenol Blue 
 
Frozen hearts were finely minced by scissors in 1 ml of lysis buffer and then 
















centrifuged at 600 g for 5 minutes at 4°C. The supernatant was transferred to a fresh 
micro-centrifuge tube and centrifuged at 10 300 g (11 500 rpm) for 10 minutes. The 
supernatant is now the cytosolic fraction and the pellet, mitochondrial fraction. The 
pellet was resuspended in 40 µl incubation buffer. Proteins were quantitated and an 
equal volume low ionic strength sample buffer was added to each sample. 
 
3.2. Lowry Protein assay 
i) CTC reagent: Solution A - Na2CO3 in 20 g/100 ml double distilled water (ddH2O) 
      Solution B - CuSO4.5H2O - 0.2 g 
       K2 tartrate  - 0.4 g  
Add solution A to B with constant stirring to prevent precipitation. 
ii) SDS 
 10 % SDS solution (w/v) 
iii) NaOH 
 0.4 g/ 200 ml ddH2O 
Equal volumes of all three reagents were mixed immediately prior to use. 
All samples were measured in duplicate. 5 µl of protein aliquot (nuclear, cytosolic, or 
mitochondrial sample) was added to 995 µl of sterile distilled water (1:200 dilution). 1 
ml of CTC reagent was added to each tube and immediately mixed. After 10 minutes 
incubation at room temperature, 500 µl of Folin‟s Reagent (diluted 1:5 with ddH2O, 
Merck, Germany) was added and mixed immediately - the half life of the reactive 
compound in the reagent is less than 8 seconds. Samples were incubated for an 
additional 30 minutes prior to optical density measurement at 750 nm on a Varian 
130 dual beam spectrophotometer (Peterson, 1977).   
Bovine Serum Albumin protein (Sigma, Germany) was used to prepare the standard 
curve and diluted to a concentration range from 10 – 200 µg/ml which was assayed 
in the same manner as the samples. 
















3.3. Western blot  
Each well on the 10% (w/v) acrylamide/ bisacrylamide gel was loaded with 100 µg of 
nuclear, mitochondrial or cytosolic protein. Gels were run for 90-120 minutes at 120 
Volts. 7 µl of PeqGold Protein marker IV (PEQLAB Ltd, UK) was loaded onto the gel 
and ran alongside the samples. Afterwards, gels were transferred overnight at 0.02 
Amps (4°C) onto polyvinylidene fluoride (PVDF) membranes (Hybond, Amersham, 
UK). Proteins were fixed to the membrane by immersion in methanol for 5 minutes 
and air-dried. The success of protein transfer was verified by staining the PVDF 
membranes with Ponceau reagent (Sigma P7170, St Louis, MO). Membranes were 
placed between two acetate sheets and digitally scanned. 
Ponceau stain was rinsed off the membranes with three 5 minute washed in Tris 
buffered saline with 0.1 % Tween (TBS-T). Membranes were blocked for 2 hours at 
room temperature with 5% fat-free milk powder made-up in TBS-T. Following three 5 
minute cycles of washes with TBS-T, membranes were robed overnight at 4 °C with 
their respective primary antibody. Following another succession of three 5 minute 
washes with TBS-T, membranes were incubated with the appropriate secondary 
antibody. 
 
3.4 Protein analysis 
Isolated perfused mouse hearts samples were collected at reperfusion and snap-
frozen in liquid nitrogen. Samples were stored at - 80 °C until protein extraction. 
Nuclear, cytosolic a d mitochondrial proteins were extracted from hearts by 
homogenization in lysis buffer. Phosphorylated states of Akt, Erk1/2, STAT-3, GSK-
3β as well as total levels of Akt, Erk1/2, STAT-3, GSK-3β, glyceraldehyde-3 
phosphate kinase (GAPDH), β-actin and VDAC were analysed by western blot using 
antibodies from Cell Signaling Technologies. Equal loading was verified with 
GAPDH, β-actin or VDAC. These proteins are products of housekeeping genes that 
do not affect infarct size. Different proteins were selected to avoid conflicting 
molecular weight with the protein of interest and/or dependant on their localization. 
Levels of phosphorylated proteins were normalized, where appropriate, to their total 
protein levels in the sample samples and in the same conditions but on a separate 
















multiplied by 100. Relative densitometry was determined with the use if 
computerized software package (Image J, NIH, USA). A minimum of 4 hearts was 
used per group. 
3.4.1 Primary and secondary antibodies 
i) Total STAT-3 
Primary antibody: STAT-3 antibody rabbit polyclonal IgG 1:4000 in 5 % (w/v) fat free 
milk TBS-T 
Secondary antibody: Anti-rabbit 1:3000 in 5 % (w/v) fat free milk TBS-T 
ii) Phosphorylated STAT-3 
Primary antibody: phospho STAT-3 (Ser 727) antibody mouse monoclonal IgG 
1:1000 in TBS-T 
Secondary antibody: Anti-mouse 1:4000 in 2.5 % (w/v) fat free milk TBS-T 
iii) Akt 
Primary antibody: Akt antibody rabbit polyclonal IgG 1:1000 in TBS-T 
Secondary antibody: Anti-rabbit 1:4000 in 2.5 % (w/v) fat free milk TBS-T 
iv) Phosphorylated Akt 
Primary antibody: Phospho-Akt (Ser473) antibody mouse polyclonal IgG 1:1000 in 
TBS-T 
Secondary antibody: Anti-rabbit 1:3000 in 5 % (w/v) fat free milk TBS-T 
v) Glycogen Synthase Kinase-3 Beta (GSK-3β) 
Primary antibody: GSK-3β antibody rabbit monoclonal IgG 1:1000 in TBS-T 
Secondary antibody: Anti-rabbit 1:4000 in TBS-T 
vi) Phosphorylated Glycogen Synthase Kinase-3 Beta (GSK-3β) 

















Secondary antibody: Anti-rabbit 1:3000 in 5 % (w/v) fat free milk TBS-T 
 
vii) p44/42 MAPK (Erk1/2) 
Primary antibody: p44/42 (Erk1/2) antibody rabbit polyclonal IgG 1:1000 in TBS-T 
Secondary antibody: Anti-rabbit 1:4000 in 2.5 % (w/v) fat free milk TBS-T 
viii) Phospho- p44/42 MAPK (Erk1/2) 
Primary antibody: Phospho-p44/42 (Erk1/2) (Thr202/Tyr204) antibody rabbit 
polyclonal IgG 1:1000 in TBS-T 
Secondary antibody: Anti-rabbit 1:4000 in 2.5 % (w/v) fat free milk TBS-T 
vii) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
Primary antibody: GAPDH (FL-335) antibody rabbit polyclonal IgG 1:3000 in TBS-T 
Secondary antibody: Anti-rabbit 1:4000 in 2.5 % (w/v) fat free milk TBS-T 
vii) β actin 
Primary antibody: β actin antibody goat polyclonal IgG 1:3000 in TBS-T 
Secondary antibody: Anti-goat 1:4000 in 2.5 % (w/v) fat free milk TBS-T 
viii) VDAC 
Primary antibody: VDAC antibody goat polyclonal IgG 1:3000 in TBS-T 
Secondary antibody: Anti-goat 1:4000 in 2.5 % (w/v) fat free milk TBS-T 
 
All antibodies were acquired from Cell Signalling Technology, USA, except GAPDH 
(Santa Cruz Biotechnology, USA). Relative densitometry was determined with the 

















4.0. Preparation of High Density Lipoprotein (HDL) 
HDL was isolated according to the protocol described by James et al., (James et al., 
1989). The blood samples were collected and HDL was extracted at the University of 
Geneva Hospital, Switzerland. Blood was collected from healthy volunteers in EDTA 
coated tubes and spun for 10 minutes at 3500 rpm. The plasma content forms a 
yellow upper layer that was pooled together. Cumulative flotation ultracentrifugation 
was used to remove LDL and VLDL from the plasma where the volume of the 
plasma was adjusted against sodium bromide (NaBr) as follows: 
 Plasma volume (ml) X 71.4 mg/ml = mg NaBr to be added, 
where 71.4 mg/ml is the pre calculated factor required to isolate VLDL and LDL from 
plasma. 
Plasma containing NaBr was transferred to a 30 ml polyallomer centrifuge tube 
(Optiseal 361625, Beckman Coulter, USA) with aid of a syringe and spun for 21 
hours at 20°C at 45 000 rpm. Afterwards, the tube was carefully removed from the 
centrifuge and placed in a custom made tube cutting apparatus (Fig 31). The VLDL 
and LDL was suspended at the top of the tube and separated by a clear middle layer 
from the HDL which resided in the bottom layer. The tube was cut at the distinction 
between the clear and VLDL/LDL layer. The remaining clear layer above the HDL 
fraction was carefully removed and discarded. The HDL fraction from all the tubes 
was pooled together into a measuring cylinder. The volume was noted and 204.1 
mg/ml NaBr was added to it based HDL‟s density of 1.21 g/ml (calculated as earlier). 
The HDL was then decanted into another centrifuge tube and spun for 20 hours at 
45 000 rpm at 20°C to further purify the HDL fraction. The HDL underwent 
delipidisation by passage through a gel filtration column in a 5M urea-phosphate 
buffered saline (PBS) solution. HDL purity was confirmed on a polyacrylamide gel 
stained with coomassie blue. The HDL was then passed through a pressurised 
concentrator apparatus before dialysis against PBS containing 1 mM EDTA to 

















Fig 31. Custom built tube cutting apparatus. After ultracentrifugation, the polyallomer tube 












































































Despite the promising results of postconditioning, in experimental studies, its 
robustness across different animal models has yielded varying degrees of success. 
Reproducibility of the postconditioning effect has not always proved to be consistent. 
Previous studies have shown that some discrepancies may exist within the current 
rat and murine models as it proved less difficult to induce cardioprotection in the 
murine model across two laboratories (Kaljusto et al., 2006).  In the seminal paper, 
Vinten-Johanssen et al. were able to reduce significantly infarct size in the canine 
model by six alternating cycles of occlusion and reperfusion but translation of this 
powerful mechanism proved unsuccessful in the pig model (Zhao et al., 2003, 
Schwartz and Lagranha, 2006). 
Postconditioning has successfully been achieved in the human heart by coronary 
angioplasty during acute myocardial infarction (Staat et al., 2005). This has further 
prompted the urgency to optimize the conditions required for this cardioprotective 
effect because the elucidation of its signaling mechanisms may provide the key to 
novel therapeutic drug development. STAT-3 (signal transducer and activator of 
transcription-3) is an important transcription factor that has been shown to be 
essential in mediating the cardioprotective effect for both ischaemic and 
pharmacological preconditioning (Smith et al., 2004, Lecour et al., 2005b). Cytosolic 
STAT-3 is phosphorylated by activation of the JAK-2 (Janus kinase-2) pathway and 
consequently forms a homodimer that translocates to the nucleus to initiate the 
transcription of pro-survival factors. Recently, phosphorylated levels of STAT-3 have 
also been detected in the mitochondria (Wegrzyn et al., 2009). There is increasing 
evidence to suggest that inhibition of the mitochondrial permeability pore (mPTP) 
prevents cell death. Glycogen synthase kinase 3-beta (GSK-3β) has been reported 
as a common target for the convergence of protective signalling pathways and 
proximal to the mPTP (Halestrap et al., 2004, Gateau-Roesch et al., 2006, Halestrap 
et al., 2007). Phosphorylation of this kinase renders it inactive and it has been 
suggested that in this form it plays a role in the inhibition of the pore opening 
(Juhaszova et al., 2004). 
In this study, we propose that age, genetic characterisation and the number of cycles 
















addition, using cardiomyocyte specific STAT-3 deficient mice, we confirm the critical 
requirement of this transcription factor in IPostC and examine the possible 
involvement of GSK-3β as a downstream target. A schematic of our proposed 
hypothesis follows in Figure 32. 
 
Fig 32. Schematic of proposed hypothesis. What factors favour ischaemic postconditioning? Are 

























The animal protocol was performed in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health, and 
was approved by the Faculty of Health Sciences Animal Ethics Committee (AEC), 
University of Cape Town (AEC reference number: 007/007). All protocols were 
carried out in compliance with the Guide for the Care and Use of Laboratory Animals 
published by the U.S. National Institutes for Health (NIH Publication No. 85 (23), 
revised 1996). Mice were bred and obtained from the University housed Animal Unit.  
Animals had access to food and water ad libitum. Cardiomyocyte-specific STAT-3-
deficient mice (STAT-3-/-) from C57Black6 background were created in our facilities 
by crossing homozygous floxed STAT-3 mice with heterozygous MLC2V-driven Cre 
recombinase mice, as previously described (Smith et al., 2004). 
 
2.1. Perfusion of isolated mouse hearts  
We compared the postconditioning parameters in pure wildtype C57 Black 6 mice to 
the genetically modified rodents that only differed in respect to the presence of two 
loxP gene fragments inserted into the myosin light chain isoform-2 ventricle (MLC2V) 
expressing gene, which correspond to the wildtype used as a control for STAT-3 
knockout studies. Wildtype male mice (C57BL/6) in the presence or absence of a 
floxed allele expression in the cardiac muscle and aged between 14-16 or 18-20 
weeks were perfused on a Langendorff retrograde perfusion apparatus as previously 
described (see Section C). Following 20 min of stabilization, the hearts were 
exposed to 35 minutes of global ischaemia and 45 minutes of reperfusion, as 
described in figure 33.  At the end of the experiment, hearts were stained with TTC 
to measure infarct size. Cardiomyocyte specific STAT-3 deficient mice were also 
perfused on the Langendorff apparatus to investigate the effect on postconditioning 
in the absence of this gene. 
To examine STAT-3 and GSK-3β levels, hearts were collected at 7 minutes of 
reperfusion following global ischaemia (Figure 33). Cytosolic and mitochondrial 

















Fig 33. Schematic representation of experimental protocol. Mouse hearts subjected to 3 x 10 
seconds of ischaemia/ reperfusion after 35 minutes global ischaemia were collected for Western blot 
analysis at the indicated time point in a separate experiment. IPostC, ischaemic postconditoning 
 
2.2. Chemical and Pharmacological Agents 
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich Chemicals, 
Germany. 
 
2.3. Statistical analysis 
Data are expressed as mean values ± S.E.M and were analysed by performing 
multiple group comparisons using one way ANOVA and followed by Student-
Newman-Keuls post hoc test or T-Test (Graph Pad Instat).  A value of P < 0.05 was 
considered to be statistically significant. A minimum of 6 hearts per group was used 























3.1. Postconditioning improves infarct size in young/ older wiltype non-
floxed mice 
To investigate the influence of age and number of cycles of postconditioning in 
wildtype mice, 14-16 or 18-20 weeks old mouse hearts were postconditioned with 
either 3 or 6 cycles of 10 seconds ischemia/reperfusion following the sustained 
ischemia (Figure 34).   Ischaemic control hearts from young and older adult had a 
comparable infarct size of 48.6 ± 1.5% and 56.8 ± 5.7%, respectively.  Application of 
3 cycles of postconditioning (IPostC-3) significantly reduced the ischaemic damage 
(infarct size of 14.2 ± 0.9% in young mice and 29.9 ± 7.5% in older mice).  Similarly, 
postconditioning with 6 cycles of ischemia/ reperfusion (IPostC-6) also proved to be 
beneficial in both the young and adult wildtype mice (16.2 ± 2.6% and 26.4 ± 3.6%, 
respectively). 
 
Fig 34. Postconditioning improves infarct size in younger/ older C57BL/6 non-floxed mice. (n ≥ 



















3.2. Age and number of cycles of postconditioning affect wildtype floxed 
mice 
As shown in Figure 35, at 14-16 weeks, infarct size which was attenuated by 3 
cycles (26.2 ± 5.3%) but not by 6 cycles of postconditioning (40.9 ± 5.0%) compared 
to the ischaemic control (51.2 ± 4.2%).  Postconditioning the older adult hearts with 
either 3 or 6 cycles produced an infarct size that did not differ appreciably from the 
ischaemic control (41.6 ± 1.7% for IPostC-3 and 38.4 ± 7.1% for IPostC-6 vs 37.9 ± 
3.8% for ischaemic control). The main finding is that the protective effect of PostC-6 
was lost in older group of floxed mice. However, the control infarct size in this group 
(37.9±3.8%) was smaller compared with the younger floxed group (51.2±4.2%) or 




Fig. 35. Age and number of cycles influence the successful effect of postconditioning in floxed 




















3.3. STAT-3 is required to confer cardioprotection in ischaemic 
postconditioning 
Three cycles of postconditioning was applied to cardiomyocyte specific STAT-3 mice 
and its respective control, aged 14-16 weeks. As observed in the pure wildtype, the 
control wildtype mice were successfully postconditioned (51.2 ± 4.2 % for ischaemic 
control vs 26.2 ± 5.3 % for IPostC, p < 0.05, Figure 36). The protective effect was 
abolished in the absence of STAT-3 (49.5 ± 5.8 % for ischaemic control vs 49.6 ± 6.5 
% for IPostC, p = ns). 
 
 
Fig. 36. The cardioprotective effect of ischaemic postconditioning is abolished in the 


























4.0 Western Blots 
4.1. Ischaemic Postconditioning increased the activation of mitochondrial 
STAT-3  
To confirm the involvement of STAT-3 in IPostC, phosphorylated levels of STAT-3 
were measured in the cytosol and mitochondria extracted from cardiomyocyte STAT-
3 deficient hearts and their respective wildtype after 7 min of reperfusion. Compared 
to the wildtype ischaemic control, there was a marked reduction in phosphorylated 
STAT-3 in the cytosol following the IPostC stimulus (In arbitrary units (AU), 1.4 ± 0.3 
AU for IC to 0.7 ± 0.3 AU for IPostC, P < 0.05, Figure 37). In contrast, 
phosphorylation of STAT-3 was significantly elevated in the mitochondrial fraction 
(0.4 ± 0.2 AU for IC to 0.8 ± 0.1 AU for IPostC, P < 0.05). This translocation effect 
was not observed in the cardiac deficient STAT-3-/-. There was no significant 
difference between the ischaemic control and IPostc groups in the cytosolic (0.6±0.3 
AU for IC to 0.6 ± 0.2 AU for IPostC, P = ns) or mitochondrial fraction (0.4 ± 0.1 AU 

























Fig 37. Western blot analysis of ischaemic postconditioning in STAT-3 deficient and their 
respective wildtype. IC, ischaemic control; IPOSTC, ischaemic postconditioning; STAT-3, Signal 




















4.2. Glycogen synthase kinase 3β levels are upregulated in ischaemic 
postconditioning 
To explore whether GSK-3β could be a possible downstream target of STAT-3, we 
examined levels of phosphorylated GSK-3β in WT and STAT-3 KO mice subjected to 
IPostC. Phosphorylated levels of GSK-3β  were measured in the similar manner as 
STAT-3. In the cytosolic fraction of wildtype mouse hearts, there was a significant 
increase of phosphorylated GSK3β levels in IPostC compared to the ischaemic 
control group (0.8 ± 0.1 AU for IC to 1.2 ± 0.1 AU for IPostC, P < 0.05). Similarly, 
phosphorylated GSK-3β levels were elevated in the postconditioned mitochondrial 
fraction compared to the ischaemic control group (0.6 ± 0.0 AU for IC to 0.8 ± 0.1 AU 
for IPostC, P < 0.05). In the absence of STAT-3, GSK-3β levels were unaffected in 
both the cytosolic and mitochondrial fraction (0.6 ± 0.2 AU for IC to 0.6 ± 0.1 AU for 
























Fig 38. Phosphorylation of GSK-3β in wildtype and STAT-3 knockout mice. IC, ischaemic 
control; IPOSTC, ischaemic postconditioning; GSK-3β, Glycogen synthase kinase-3 beta; STAT-3, 




















This study demonstrated that wildtype mice in the absence of a floxed gene are 
more prone to responding effectively to postconditioning.  This was further evident 
with the older adults when a minor age difference of two weeks completely abolished 
the IPostC effect in the floxed mice.  Additionally, the number of postconditioning 
cycles also played an important role in the wildtype strains that determined the 
extent of afforded cardioprotection. In addition, our data suggest that STAT-3 was 
essential in mediating the cardioprotective effect and involved in the regulation of 
phosphorylated GSK-3β during IPostC.  
 
5.1. Minor difference in age, number of cycles and genetic characterisation are 
critical parameters that can affect the outcome of ischaemic postconditioning 
Postconditioning is a recently discovered phenomenon that can elicit profound 
protection if administered timeously following a myocardial infarction.  It was first 
demonstrated successfully in an in vivo canine model of one hour left anterior 
descending (LAD) coronary artery occlusion using an algorithm of 30 seconds 
reperfusion and 30 seconds re-occlusion, repeated for 3 cycles and then continued 
reflow for the remaining 3 hours duration (Zhao et al., 2003).  The resultant infarct 
size reduction was found to be strongly comparable to that of the phenomenon of 
ischaemic preconditioning (whereby small episodes of ischemia-reperfusion are 
performed prior to the major ischaemic insult (Murry et al., 1986).  Interestingly, 
postconditioning across different animal models has not always met with similar 
levels of success.  Kaljusto et al experienced difficulties when they conducted a 
study across two laboratories and while both groups were unable to postcondition 
the in vitro rat heart, only one group managed to successfully accomplished 
cardioprotection in the in vivo rat heart (Kaljusto et al., 2006).  Discrepancies 
between the in vitro and in vivo model may be due to differences in antixodant 
activity, neutrophils or other blood elements (Kin et al., 2004, Zhao et al., 2003, 
Kaljusto et al., 2006). Similarly, other studies have also had difficulties with 
postconditioning.  Duplication of the postconditioning protocol as originally presented 
in the dog model failed to be cardioprotective in an in vivo pig study (Schwartz and 
















dog and pig heart, it is unlikely to affect postconditioning. All reported studies have 
been conducted in animals housed in an animal facility. 
Postconditioning reduced lethal ventricular arrhythmias in an in vivo rat model but 
failed to reduce infarct size (Dow and Kloner, 2007). All these discrepancies suggest 
that many critical factors are not controlled yet and need to be taken into 
consideration. 
A successful postconditioning outcome is also influenced by the number and length 
of cycles of ischemia and reperfusion that follow the prolonged ischemia.  Yang et al. 
showed that alteration of the postconditioning cycles afforded protection in the 
isolated rabbit heart model (Yang et al., 2005).  Similarly, our experiments 
demonstrated that only postconditioning with 3 cycles was successful in reducing 
infarct size in the floxed mice at 14-16 weeks whereas postconditioning the hearts in 
non-floxed mice appeared more robust. An insertion of 2 loxP gene fragments into 
the MLC2V targeted gene is usually thought to be silenced but may influence the 
successful effect of postconditioning. STAT-3 is a transcription factor that is essential 
in mediating the cardioprotective effect of ischaemic postconditioning (Boengler et 
al., 2008, Lacerda et al., 2009). However, abnormal alterations in STAT-3 levels 
have shown to be detrimental to the heart. The lack of cardiac STAT-3 lead to dilated 
cardiomyopathy and overstimulation of STAT-3 caused inflammation, adverse 
remodeling and heart failure (Hilfiker-Kleiner et al., 2004, Hilfiker-Kleiner et al., 
2010). Although never described in the literature, STAT-3 may have a critical role in 
the development process of the heart, which the insertion of lox P may interfere with 
at 16-18 weeks. An effect of lox P has previously been reported with 
hyperandrogenization in male mice containing a floxed allele of the androgen 
receptor gene (MacLean et al., 2008).  
 
An age difference study conducted by Fenton et al. showed that the absence of 
postconditioning-induced protection in rats at 22 months (Fenton et al., 2000).   In 
our study, we were surprised to report that a minor age difference in floxed mice 
from 14-16 weeks to 18-20 weeks can negatively affect the outcome of 
















wildtype mice which were still able to be postconditioned at 18-20 weeks.  A minor 
gene modification to allow for the creation of genetic knockout mice should not be 
expected to interfere with the initiation of cardioprotection.  Our data reinforce the 
concept that studies employing the use of genetically modified animals should 
strongly consider the littermate controls instead of simply using wildtype mice in their 
control group, especially with regard to studies related to cardioprotection.  Recently, 
it was demonstrated that a modification to a more robust postconditioning protocol 
(extension of the number of cycles) was required to induce protection in an in vitro 
aged (> 13 months) mouse model (Bouhidel et al., 2008).  
Other critical factors influencing postconditioning also need to be considered.  The 
beneficial effects of postconditioning are limited to coronary occlusions of less than 
45 min in the in vivo rat model (Tang et al., 2006).  Also, the maintenance of acidosis 
by postconditioning during the first minutes of reperfusion is critical to inhibit opening 
of the mPTP (Cohen et al., 2007).  Temperature is another important factor to be 
considered. The successful outcome of postconditioning in the in vitro rat heart was 
recently shown to be highly dependent upon the maintenance of temperature at 
37°C as the slightest fluctuations abrogated its protective effect (van Vuuren et al., 
2008).  Alteration in body temperature may create an unfavourable environment for 
essential enzymatic reactions. It is also possible that divergent pathways may exist 
not only from preconditioning but also between animal models of postconditioning.  
Activation of ERK was exhibited in the absence of PI3K-Akt in the postconditioned 
rabbit model (Darling et al., 2005).  This is in contrast to PI3K-Akt involvement in the 
pre- and postconditio ed in vitro rat heart model (Tsang et al., 2004).  It was also 
possible to postcondition the pig model using a modified protocol that was 
independent of these kinases, previously thought essential for protection (Skyschally 
et al., 2009).  
Obesity is a common cause of cardiovascular disease.  In a recent study, 
postconditioning failed to induce cardioprotection in leptin-deficient (ob/ob) mice 
(Bouhidel et al., 2008).  In addition, there are a number of risk factors such as 
diabetes, hyperlipidemia, insulin resistance, hypertension and heart failure that may 

















5.2. STAT-3 is required for ischaemic postconditioning 
STAT-3 has been previously demonstrated as a critical requirement in 
cardioprotective studies (Smith et al., 2004). At the time of this study, its role in 
IPostC had yet to be determined and verified in a cardiac specific model. Suleman et 
al. abolished the infarct sparing effect ischaemic postconditioning with JAK2 inhibitor, 
AG490 in the isolated rat heart model (Suleman, 2006). Decreased cytosolic levels 
of phosphorylated STAT-3 following IPostC, was observed by western analysis, 
suggesting activation and nuclear translocation of STAT-3. Schulz and colleagues 
also confirmed the essential role for STAT-3 in IPostC in an in vivo cardiac specific 
deficient STAT-3 mouse model (Boengler et al., 2008). Similarly, an interaction 
between the JAK/STAT-3 pathway and PI3-kinase/ Akt pathway to explain IPostC‟s 
beneficial effects is suggested (Goodman et al., 2008). Recently, we demonstrated 
the activation of the prosurvival SAFE pathway in IPostC (Lacerda et al., 2009). 
TNFα was shown to mediate the protective signal via its TNF receptor 2 and STAT-
3. IPostC failed to reduce infarct size in TNF-/- and TNFR2-/- mice. In this study, 
mouse hearts were also pharmacologically postconditioned with TNFα which was 
dependant on the activation of STAT-3 but independent of the RISK pathway, which 
involves the PI3-K/ Akt and ERK1/2 kinases.  
Inactivation of GSK-3β by phosphorylation has been established as a downstream 
target in cardioprotection and implicated in mitochondrial permeability pore inhibition 
(Juhaszova et al., 2009, Gross et al., 2006). However, its mechanism of action is 
unclear. We were interested in whether or not GSK-3β may be regulated by STAT-3 
in IPostC. Our studies showed that phosphorylated GSK-3β was elevated in both 
cytosolic and mitochondrial fractions obtained from the wildtype hearts following 
IPostC. Our findings are consistent with those of Nishihara et al. who also 
demonstrated a mitochondrial translocation of GSK-3β following an ischaemic 
preconditioning stimulus (Nishihara et al., 2007). It is suggested that GSK-3β 
translocation may employ Translocase of the Outer mitochondrial Membrane 20 
(TOM20) (Rodriguez-Sinovas et al., 2006). In our experiments, GSK-3β levels were 
unaffected in STAT-3-/- hearts with IPostC treatment, suggesting that STAT-3 may be 
involved in the regulation of this kinase in IPostC. However, this does not prove that 
GSK-3β is essential to IPostC induced protection and its involvement has been 
















able to successfully postcondition hearts from homozygous GSK-3 double knockin 
mice (GSK-3α and GSK-3β isoforms were inhibited) (Nishino et al., 2008). In 
contrast, Juhaszova et al. demonstrated that GSK-3β was essential for protection in 
their cardiomyocyte model (Juhaszova et al., 2004). Genetically modified mice 
expressing constitutely active GSK-3β that cannot be inactivated by phosphorylation 
of its serine 9 residue, failed to be postconditioned and GSK-3β inactivation was 
suggested to exert its cardioprotective effects via inhibition of the mPTP (Juhaszova 
et al., 2004). It may be possible that under certain conditions, GSK-3β is regulated 
by divergent signalling mechanisms.  
 
5.3. Conclusion 
Postconditioning represents a means to harness the myocardium‟s endogenous 
capacity to resist damage.  The aged heart has an increased susceptibility to 
damage and therefore it is imperative to unravel the complexity of its signaling 
mechanisms so that novel therapeutic agents may be developed to elicit 
postconditioning.  Our data strongly suggests that the genotypic characteristics of 
the mouse, the age and the number of postconditioning cycles are critical factors to 
be considered in ischaemic postconditioning. Different animal models may require 
different postconditioning protocols.  Additional factors such as humidity and stress 
also require investigation.  It might be possible that the discrepancies observed in 
the floxed mice may be due to the dysregulation of gene programs that attenuate the 
postconditioning effect.  These factors should be taken into consideration for future 
experimental research or clinical applications of this protective phenomenon. STAT-3 
has also been demonstrated as an essential factor in ischaemic postconditioning. 
Since it forms part of the prosurvival SAFE pathway, it would be interesting to further 
explore its role in cardioprotection as it may represent a novel therapeutic target 

















Fig 39. Summary of our data. Age, postconditioning cycles and genetic characteristics are critical to 
the successful outcome of ischaemic postconditioning. STAT-3 is an essential to mediating 
cardioprotection but GSK-3β‟s role is questionable. IPostC, ischaemic postcondtioning; STAT-3, 
































E. CLASSICAL PHARMACOLOGICAL AGENTS USED AS 















Part of the experiments in this section have been performed in conjunction with Dr Lydia Lacerda at 

















Ischaemic postconditioning represents a promising clinical intervention to reduce 
myocardial infarction to the ischaemic heart. However, its clinical application, by 
inflation/ deflation of the balloon or with the pressure cuff may not always be 
practical, as it needs to be performed at a critical time when every minute counts to 
save the life of the patient. Pharmacological postconditioning with the administration 
of a drug would certainly be more practical. For this, a greater understanding of the 
mechanisms involved in the postconditioning phenomenon is required. Adenosine, 
bradykinin and opioids are three compounds released during ischaemic 
preconditioning but it is unknown whether these drugs may postcondition the heart.  
In the previous section of this thesis, we demonstrated that ischaemic 
postconditioning can mediate cardioprotection via the activation of the SAFE 
pathway involving TNFα and STAT-3 (Lacerda et al., 2009). But the role of the SAFE 
pathway in adenosine, bradykinin and opioid induced cardioprotection has never 
been explored. 
Therefore, the aim of this study was to explore the benefit of pharmacological 
postconditioning with adenosine, bradykinin and opioids compared to ischaemic 
postconditioning and to investigate the role of the SAFE pathway as the 
cardioprotective effect. 
To explore this aim, TNFα knockout, cardiomyocyte specific STAT-3 deficient mice 
(STAT-3-/-) and their respective wildtypes will be subjected to an ischaemia/ 
reperfusion insult on the isolated mouse heart model. Ischaemic or pharmacological 
postconditioning (with adenosine, bradykinin and opioids) will be performed at the 
onset of reperfusion and infarct size will be used as an end point. Since STAT-3 has 
been recently identified in the mitochondria, an organelle considered as the putative 
end target for postconditioning, we used the western blot technique to evaluate the 
possible activation of STAT-3 in the mitochondria following a pharmacological 
stimulus (Wegrzyn et al., 2009, Heusch et al., 2010). A schematic of our proposed 

















Fig 40. Schematic of proposed hypothesis. Pharmacological postconditioning with adenosine, 
bradykinin and opioids induce cardioprotection via activation of TNFα and the subsequent 
phosphorylation and mitochondrial translocation of STAT-3. TNFα, Tumour Necrosis Factor-alpha; 






























All animal studies performed in this chapter complied with the recommendations laid 
down in the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85 (23), revised 1996) and were 
approved by the the Faculty of Health Sciences Animal Ethics Committee, University 
of Cape Town (AEC reference number: 006/021 and 010/033). Six mice were used 
per experimental group. Cardiomyocyte-specific STAT-3-deficient mice (STAT-3-/-) 
from C57Black6 background were created in our facilities by crossing homozygous 
floxed STAT-3 mice with heterozygous MLC2V-driven Cre recombinase mice, as 
previously described (Smith et al., 2004). Homozygous TNFα-deficient mice were 
also used. Mice used in this study were 12-14 weeks of age. 
 
2.1 Pharmacological postconditioning with classic cardioprotective agents 
Adenosine (100 µM), bradykinin (100 nM), and delta opioid agonist, D-Ala 2‟, D-Leu 
5‟- enkephalin acetate salt (DADLE, 100 nM) were given at the onset of reperfusion 
as postconditioning mimetics to isolated mouse hearts from TNF-/- and STAT-3-/- 
mice and their respective wildtypes. 
 
2.2.1 Perfusion of mouse hearts 
Hearts from adult male TNFα-/- and STAT-3-/- mice and their respective wildtypes 
were isolated and perfused on the Langendorff retrograde apparatus as described in 
Section C. An IPostC protocol of 6 x 10 seconds alternating cycles of ischaemia/ 
reperfusion (I/R) was selected because TNFα-/- mouse hearts could not be protected 
with 3 x 10 seconds alternating cycles of I/R at 12-14 weeks of age. Adenosine, 
bradykinin and DADLE were given to the hearts at the onset of reperfusion following 
the extended ischaemic insult via 6 x 10 seconds alternating cycles of reperfusion 
and reperfusion together with each of the pharmacological agents in turn as outlined 

















Fig 41. Schematic of the Langendorff experimental protocol. Isolated mouse hearts were 
perfused for 20 minutes followed by 35 minutes global ischaemia and a 45 minute reperfusion period. 
Ischaemic postconditioning (IPostC) was initiated at the onset of reperfusion with 6 x 10 seconds of 
alternating of ischaemia/ reperfusion. In a separate group, pharmacological postconditioning with 100 
µM adenosine, 100 nM Bradykinin or 100 nM DADLE was initiated with 6 x 10 secs of intermittent 
reperfusion. 
 
2.2.2 Infarct size assessment 
At the end of the experiment, hearts were stained with triphenyltetrazolium chloride 
to measure infarct size, as described previously (Smith et al., 2002).  Hearts were 
then frozen overnight and sectioned into 1.5 mm slices.  The slices were tightly 
placed between two glass plates at a distance of 0.5 mm apart and digitally scanned.  
A minimum of 6 hearts per group was used in this study. Infarct size was calculated 
using computerized planimetry (Planimetry+, Boreal Software, Norway). 
 
2.3. Western Blot analysis 
Control or postconditioned hearts with adenosine, bradykinin, or DADLE, were 
subjected to 20 min stabilization, 35 min global ischaemia followed by 15 min 
reperfusion. At this point, hearts were snap frozen in liquid nitrogen and stored at -
80°C, until protein extraction could be performed. Cytosolic and mitochondrial 
extractions were performed as previously described in Section C. Phosphorylated 
















dodecyl sulphate polyacrylamide gel immunoelectrophoresis (SDS-PAGE). Equal 
loading was verified by measuring levels of β-actin (cytosol) or VDAC (mitochondria). 
Relative Densitometry analysis was carried out using a computerized software 
package (Image J analysis and processing in Java). A minimum of six hearts per 
group were used. 
 
2.4. Chemicals and pharmacological agents 
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich chemicals, 
Germany. Western blot antibodies were obtained from Cell Signaling Technologies, 
USA and Santa Cruz Biotechnology, Inc, USA. 
 
2.5. Statistical analysis 
Data are expressed as mean values ± S.E.M and were analysed by performing 
multiple group comparisons using one way ANOVA and followed by Student-
Newman-Keuls post hoc test or T-test (Graph Pad Instat).  A value of P<0.05 was 



























3.1. Pharmacological postconditioning with classic cardioprotective agents 
in the presence or absence of TNF 
Ischaemic postconditioning significantly improved infarct size in the TNF-WT mice 
compared to the ischaemic control group (IC) (17.1 ± 1.2% for IPostC vs 46.0 ± 0.8% 
for IC, p < 0.05, Figure 42). Similarly, bradykinin, DADLE and adenosine attenuated 
the infarct size in TNF-WT hearts (19.0 ± 1.1% for bradykinin postconditioning (Bk-
PostC), 23.8 ± 1.3% for DADLE postconditioning (D-PostC), and 14.7 ± 1.3% for 
adenosine postconditioning (Adeno-PostC) vs IC, p < 0.05). In contrast, this 
protective effect was abolished in IPostC, Bk-PostC and D-PostC hearts in the 
absence of the TNFα gene (47.8 ± 1.3% for IPostC, 47.1 ± 1.4% for Bk-PostC, and 
48.9 ± 1.2% for D-PostC vs 47.1 ± 1.2% for IC, p = ns). Surprisingly, adenosine 
induced a cardioprotective effect in TNFα-deficient mouse hearts against ischaemia 
reperfusion injury (19.2 ± 1.3% for Adeno-PostC vs IC, p < 0.05). 
 
Fig 42. Classic cardioprotective agents fail to protect hearts in TNFα-/- mice except for 
adenosine. *p< 0.05 vs IC (TNF-WT), #p < 0.05 vs IC (TNFα
-/-
), n=6. IC, ischaemic control; Bk-PostC, 





















3.2. STAT-3 is essential for pharmacological postconditioning with 
bradykinin, DADLE and adenosine 
In STAT-3-WT mice, ischaemic postconditioning reduced infarct size from 46.0 ± 
2.8% in the ischaemic control group to 23.1 ± 4.5% for IPostC (Figure 43, p < 0.05). 
Similarly, Bk-PostC, D-PostC and Adeno-PostC also protected STAT-3-WT hearts 
by reducing infarct size from 39.9 ± 2.4% in the ischaemic control group to 20.1 ± 
4.1%, 18.2 ± 1.7%, and 21.9 ± 2.6%, respectively (P < 0.05 vs IC). None of the 
postconditoning protocols were effective in reducing infarct size in the STAT-3 
deficient mice (49.8 ± 5.4% for IPostC, 41.3 ± 2.7% for Bk-PostC, and 39.2 ± 1.9% 
for D-PostC, and 37.2 ± 4.6% for Adeno-PostC vs 39 ± 2.4% for IC, p = ns). 
 
Fig 43. The beneficial effect of postconditioning with bradykinin, DADLE and adenosine is 
cardioprotective in STAT-3-WT but lost in STAT-3
-/-
 mice. *p< 0.05 vs IC (TNF-WT), n=6. IC, 
ischaemic control; Bk-PostC, bradykinin postconditioning; D-PostC, DADLE postconditioning; Adeno-























3.3. Western blot analysis 
The mitochondrial and cytosol activation of STAT-3 was investigated after 
pharmacological postconditioning in TNF-WT and TNFα-/- mice (Figure 44). In the 
mitochondria isolated from TNF-WT hearts, we observed a significant increase in 
phosphorylated STAT-3 after postconditioning with bradykinin and DADLE (1.6 ± 0.2 
AU for Bk-PostC, and 1.8 ± 0.2 AU for D-PostC vs 0.8 ± 0.2 AU for IC, p < 0.05) but 
not with adenosine (1.2 ± 0.1 AU for Adeno-PostC vs IC, p = ns). In constrast, there 
was no significant change in STAT-3 phosphorylation following treatment of the 
postconditioning mimetics in TNFα-/- mitochondria (1.3 ± 0.3 AU for Bk-PostC, 1.7 ± 
0.3 AU for D-PostC and 1.6 ± 0.4 AU for Adeno-PostC vs 1.5 ± 0.3 AU for IC, p = 
ns). In the WT cytosolic fraction, phosphorylated STAT-3 tend to decrease following 
the treatment with all postconditioning mimetics but only D-PostC showed a 
significant decrease in STAT-3 phosphorylation (0.7 ± 0.1 AU for D-PostC vs 1.3 ± 
0.2 AU for IC, p < 0.05). In the absence of TNFα (as in TNFα-/-), there was no 
significant increase in cytosolic phosphorylation observed in any of the 

















Fig 44. The mitochondrial translocation of phosphorylation STAT-3 following pharmacological 
postconditioning with bradykinin, DADLE and adenosine. *p < 0.05 vs IC, n=4. IC, ischaemic 





















In this study, we investigated the postconditioning potential of classic 
pharmacological agents, namely, adenosine, bradykinin and opioids. 
Pharmacological postconditioning with these agents conferred cardioprotection in 
WT isolated mouse hearts subjected to an ischaemia/ reperfusion insult to a similar 
extent to ischaemic postconditioning. Interestingly, we found that bradykinin and 
opioids conferred cardioprotection via activation of the SAFE pathway as both TNFα-
/- and STAT-3 knockout mice failed to be protected with bradykinin and opioids. In 
contrast, adenosine could confer cardioprotection in TNFα-/- but not in STAT-3-/- 
mice, therefore suggesting a partial activation of the SAFE pathway with adenosine.  
4.1. Adenosine as a postconditioning mimetic 
Adenosine is one of many known autacoids that are released during the ischaemic 
postconditioning (Ovize et al., 2010). Interstitial levels f the nucleoside are 
increased during ischaemia and washed out during reperfusion (Schulz et al., 1995). 
Adenosine has multiple receptor subtypes (A1, A2A, A2B, and A3) that are expressed 
in the myocardium and vasculature which have been exploited therapeutically with 
mixed results (Baxter et al., 2000, Burley and Baxter, 2009). Recent studies 
suggesting the endogenous activation of adenosine receptors by ischaemic 
postconditioning has renewed interest in the nucleoside as a cardioprotective agent. 
Hence, Kin et al. proved that postconditioning the isolated mouse heart delayed the 
intravascular adenosine washout and significantly reduced infarct size (Kin et al., 
2005). They also employed an open-chest rat model where postconditioning 
produced an infarct limiting effect that was abolished in the presence of an A2, A3 or 
non-selective AR antagonist but not with an A1AR antagonist. This study suggested 
that IPostC increases the endogenous adenosine levels that activate A2 and A3 AR 
subtypes to confer cardioprotection. Park et al also showed protection at reperfusion 
with an A3 AR agonist (Park et al., 2006). The protective effects of A2A and A2B AR 
activation have specifically been demonstrated in mouse (A2A) (Rork et al., 2008), rat 
(A2A and A2B) (Lasley et al., 2007), rabbit (A2B) (Kuno et al., 2008), and dog (A2A) 
(Glover et al., 2007). Previously, Yang et al. also provided evidence that the 
beneficial effect of postconditioning was dependant on adenosine receptors and 
















antagonist to block protection (Yang et al., 2005). Use of specific antagonists 
identified A2B AR as a likely target for mediating protection.  
Clinical trials with adenosine (Acute Myocardial Infarction Study of Adenosine – 
AMISTAD I and II) showed a significant reduction in infarct size but a weak clinical 
outcome in patients with a ST-segment elevation myocardial infarction undergoing 
reperfusion therapy (Ross et al., 2005, Mahaffey et al., 1999). At the end of 
AMISTAD II, insufficient data was obtained to substantiate adenosine as a viable 
treatment. However, fewer adverse effects were reported with the lower dosage of 
adenosine (70 µg/kg/min) and a larger scale study was proposed. Intravenous 
delivery of adenosine has been confounded by the side effects of hypotension and 
bradycardia. However, Takahama et al. have recently developed a novel technique 
whereby adenosine, encapsulated in polyethylene glycol-coated liposomes were 
infused at reperfusion and successfully reduced infarct size in ischaemic rats with no 
significant effects on the mean blood pressure or heart rate compared to free 
adenosine infusion (Takahama et al., 2009). The findings in our study support 
adenosine as a treatment option against reperfusion injury as a postconditioning 
mimetic. Although TNFα did not contribute to the cardioprotective effect of adenosine 
as a postconditioning mimetic, STAT-3 was critical to the postconditioning outcome. 
Interestingly, previous work in our laboratory showed that successful preconditioning 
with adenosine was also dependant on STAT-3 but not TNFα (Smith et al., 2002, 
Smith et al., 2004). Erk 1/2 or PKC activation have previously been linked to STAT-3 
phosphorylation and may be involved (Frias et al., 2009, Xuan et al., 2001). It is 
possible that the signalling mechanism may involve adenosine, acting via its 
preferred adenosine receptor subtype to stimulate STAT-3 activation through Erk 1/2 
or PKC. This may be followed by the subsequent translocation of STAT-3 from the 
cytosol to the mitochondria, as observed by the concomitant increase in STAT-3 
phosphorylation levels. Another possibility would be that adenosine is part of the 
SAFE pathway and somehow, is an intermediate compound activated by TNFα but 



















4.2. Bradykinnin and opioids activate the SAFE pathway in pharmacological 
postconditioning 
Bradykinin and opioids are released from the myocardium after ischaemia. 
Preconditioning with these autacoids has shown to have a cardioprotective effect 
(Gross et al., 2004, Gross and Gross, 2006). Exogenous administration of bradykinin 
at reperfusion successfully limited reperfusion injury (Bell and Yellon, 2003). The B2 
receptor has been implicated as a likely candidate for triggering the cardioprotective 
event since B2 receptor antagonists, icatibant and WIN64338 abrogated the 
postconditioning effect (Penna et al., 2007). This was confirmed in B2 receptor 
knockout mice. An additive cardioprotective role for the B1 receptor was suggested 
when ablation of the gene partly attenuated infarct size (Xi et al., 2008). The 
signalling mechanisms involved in the process are unclear but a role for the RISK 
pathway, eNOS and prostaglandin (PGI2), has been suggested (Penna et al., 2008, 
Bell and Yellon, 2003). 
With regards to opioids, Zatta et al. showed that IPostC preserved the myocardial 
opioid peptide concentrations during early reperfusion (Zatta et al., 2008). IPostC 
was abolished in the in vivo rat myocardium with the addition of non-selective 
agonist, naloxone or selective δ-opioid receptor antagonist, naltrindole (Jang et al., 
2008). Interestingly, Chen et al. implicated the κ- but not δ-opioid receptor in 
morphine induced postconditioning of the isolated rat heart (Chen et al., 2008). 
There is a lack of knowledge of exogenous opioids given at reperfusion to limit 
reperfusion injury. Recently, morphine was given for 15 minutes at the onset of 
reperfusion after the ischaemic event and found to reduce infarct size comparable to 
ischaemic postconditioning (Huhn et al., 2010). 
We applied a pharmacological postconditioning protocol on the isolated mouse heart 
whereby bradykinin or opioids were delivered via means of stuttered reperfusion. In 
contrast to the results obtained with adenosine, cardioprotection with these agents 
were dependant on both TNFα and STAT-3. Here, we provide evidence for the 
existence of prosurvival signalling pathways and implicate the SAFE pathway in 

















4.3. STAT-3 activity in the mitochondria 
The role for STAT-3 in ischaemic postconditioning has been demonstrated earlier in 
this thesis, whereby the genetic ablation of the gene completely abolished 
cardioprotection (section D). The recent discovery of STAT-3 in the mitochondria, 
phosphorylated at its serine residue suggested that the cardioprotective effect 
observed with STAT-3 in pre- and postconditioning may be related to its activation 
within the mitochondria rather than the nucleus (Wegrzyn et al., 2009). Hence, 
Wegrzyn et al. showed that STAT-3 was critical to the mitochondrial electron chain 
transport system and thus cellular homeostasis. Mice that do express STAT-3 in the 
heart exhibit defects in complexes I and II of the electron transport chain in the 
mitochondria which effect cellular homeostasis (Wegrzyn et al., 2009). The exact 
mechanism by which STAT-3 regulates complexes I and II remains to be 
determined. STAT-3 is known to regulate anti-apoptotic factor, Bcl-xL, located on the 
outer mitochondrial membrane (Lin et al., 2005, Zhang et al., 2007b). We observed 
an increase in the ratio of phosphorylated STAT-3 in the mitochondrial fraction, 
compared to the cytosolic fraction in hearts treated with bradykinin or DADLE. This 
may suggest a prosurvival signalling pathway involving STAT-3 translocation from 
the cytosol to the mitochondria. Interestingly, adenosine‟s cardioprotective effect was 
abolished in the absence of STAT-3. However, our western blot analysis did not 
reveal the expected increase in mitochondrial STAT-3 levels. It is possible that 
adenosine induced protection may require an additional mechanism of action for 
STAT-3 linked to its cytosolic activation or perhaps, translocation to the nucleus. 
Our novel data show that pharmacological postconditioning with bradykinin and 
opioids activate STAT-3 via TNFα, and thus the SAFE pathway, to confer protection 
against reperfusion injury (Figure 45). The low levels of STAT-3 detected in the 
mitochondria may suggest a “kinase-like” activity for the transcription factor in the 
signalling cascade. Further studies into the elucidation and dynamics of the multiple 
prosurvival pathways involved in ischaemic and pharmacological postconditioning is 
warranted as this may lead to potential clinical and novel therapeutic drug 
development. STAT-3 is involved in the regulation of genes in the nucleus which 
may encode proteins that are involved in the preservation of mitochondrial potential. 


















Fig 45. Summary of findings. Bradykinin and DADLE stimulated the activation of TNFα and 
subsequent phosphorylation of STAT-3 (SAFE pathway) leading to cardioprotection. Pharmacological 





















































Part of this work was done in collaboration with Dr Miguel Frias and Prof Richard James of University 

















Lipoproteins are macromolecular structures that are composed of free cholesterol, a 
core of cholesteryl esters, triglycerides and surrounded by an envelope of 
phospholipids (Figure 46) (Libby, 2008). There are five major classes of lipoproteins, 
chylomicrons, Very Low Density Lipoprotein (VLDL), Intermediate Density 
Lipoprotein (IDL), Low Density Lipoprotein (LDL) and High Density Lipoprotein 
(HDL). HDL is the smallest of the lipoproteins but are also the most dense as they 
are enriched with apolipoproteins, Apo A-I and Apo A-II. These apolipoproteins 
assist HDL in the removal of excess LDL-cholesterol via the reverse cholesterol 
transport. HDL is considered as the „good cholesterol‟ and elevating its levels with 
statins, fibrates and other lipid-lowering drugs are used to treat patients with 
coronary artery disease (Brown et al., 2006, Otvos et al., 2006, 1984). HDL also 
possesses many other cardiovascular benefits due to its anti-inflammatory, anti-
oxidant, anti-apoptotic and vasodilatory properties (Barter et al., 2004, Mineo et al., 
2006, Argraves and Argraves, 2007).  
 
Fig 46. Structure of lipoproteins. Phospholipids form the envelope of the structure where the polar 
groups are directed towards the aqueous environment. Free cholesterol is located within the 
phospholipid layer. Cholesteryl esters and triglycerides make up the core of the lipoprotein. 
Apolipoproteins are involved in the secretion of the lipoprotein, afford structural integrity, and function 
as cofactors for enzymes or as ligands for different receptors. (From Braunwald‟s Heart Disease: A 

















In a setting of ischaemia/ reperfusion injury, HDL reduced harmful TNFα levels when 
administered either prior or after the ischaemic insult (Calabresi et al., 2003). 
Recently, S1P has been identified as a constituent of HDL and has been suggested 
to be responsible for mediating some of its protective effects (Theilmeier et al., 2006, 
Kimura et al., 2001, Okajima, 2002, Frias et al., 2009, Frias et al., 2010). Levkau and 
colleagues demonstrated that HDL and S1P protected the in vivo mouse 
myocardium from ischaemia/ reperfusion injury via nitric oxide and S1PR3 
(Theilmeier et al., 2006). Frias et al. showed native and reconstituted HDL with a 
varied composition of S1P protected cardiomyocytes against doxorubicin induced 
apoptosis via S1PR2 but not S1PR1 and S1PR3 (Frias et al., 2010). In a separate 
study, this group also implicated a role for prosurvival factors STAT-3 and ERK1/2 in 
HDL induced cardioprotection (Frias et al., 2009). 
The addition of S1P or sphingosine after forty minutes of ischaemia significantly 
improved left ventricular developed pressure and elevated depleted levels of Akt, a 
prosurvival kinase of the well established Reperfusion Injury Salvage Kinase (RISK) 
pathway (Vessey et al., 2008a, Tsang et al., 2004). The combined addition of the 
sphingolipids extended the protection after more prolonged periods of ischaemia. 
This additive effect is explained by the different mechanisms of each agent. S1P 
functions through a G-coupled protein receptor pathway and sphingosine through a 
cyclic nucleotide pathway (Vessey et al., 2008b). Similar to preconditioning, IPostC 
was abolished in SPK1-/- mice (Jin et al., 2008). These studies suggest that the 
signalling mechanisms involved in pharmacologically induced pre- and 
postconditioning with S1P may be closely related. Recently, a novel cardiac 
prosurvival path named the Survivor Activating Factor Enhancement (SAFE) 
pathway and involving the activation of tumor necrosis factor alpha (TNFα) and the 
transcription factor signal transducer and activator of transcription-3 (STAT-3) has 
been delineated (see review (Lecour, 2009)). In this thesis, we have demonstrated 
the role of the SAFE pathway in both ischaemic and pharmacological 
postconditioning such as bradykinin and opioids. Although S1P is capable of 
activating STAT3 in cardiomyocytes (Frias et al., 2009), the necessity for S1P to 

















We thus hypothesized that HDL/ S1P protects the heart against reperfusion injury via 
the activation of the SAFE pathway and we propose to investigate a possible 
interplay between the two powerful cell survival pathways, namely the SAFE and the 
RISK path (Figure 47.).  
 
Fig 47. Schematic of proposed hypothesis. The cardioprotective properties of HDL may be 
attributed to S1P and activation of the SAFE and RISK pathways. HDL, High Density Lipoprotein; 
S1P, Sphingosine 1-Phosphate; RISK, Reperfusion Injury Salvage Kinase; MEK, Mitogen activated 
protein kinase Extracellular regulated Kinase; ERK, Extracellular Regulated Kinase; PI3K, 
Phosphoinositol 3-Kinase; SAFE, Survivor Activation Factor Enhancement; TNFα, Tumour Necrosis 
Factor alpha; JAK, Janus Kinase; STAT-3, Signal Transducer and Activator of Transcription-3. 
 
2.0. Methods 
The investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85 (23), 
















Animal Ethics Committee, University of Cape Town under AEC reference number 
009/052. Cardiomyocyte-specific STAT-3-deficient mice (STAT-3-/-) from C57Black6 
background were created in our facilities by crossing homozygous floxed STAT-3 
mice with heterozygous MLC2V-driven Cre recombinase mice, as previously 
described (Smith et al., 2004). Homozygous TNFα-deficient mice were also used. All 
mice were 14–16 weeks of age. 
 
2.1.1. Perfusion of mouse hearts 
The Langendorff perfusion model was discussed earlier in Section C. All hearts were 
subjected to 20 min of stabilization, 35 min global ischaemia and 45 min reperfusion 
(Figure 48). Hearts were treated with HDL (200 µg/ml) or S1P (10 nM) for the first 7 
minutes of reperfusion. To determine the involvement of the SAFE and RISK 
pathways, AG490 (AG), an inhibitor of the JAK/STAT pathway (100 nM), 
Wortmannin (W), a Phosphotidylinositol-3 Kinase (PI-3K)/Akt (100 nM) inhibitor, or 
PD98059 (PD), an inhibitor of the MEK/ERK pathway (100 nM) was perfused 
together with S1P or alone for 15 min after ischaemia.  
 
Fig 48. Schematic representation of the experimental protocol. Isolated hearts were subjected to 
35 min ischaemia followed by 45 min reperfusion. At the onset of reperfusion, HDL (200 µg/ml) or 

















2.1.2. Infarct size assessment 
At the end of the experiment, hearts were stained with triphenyltetrazolium chloride 
to measure infarct size, as described previously (Smith et al., 2002).  Hearts were 
then frozen overnight and sectioned into 1.5 mm slices.  The slices were tightly 
placed between two glass plates at a distance of 0.5 mm apart and digitally scanned.  
A minimum of 6 hearts per group was used in this study. Infarct size was calculated 
using computerized planimetry (Planimetry+, Boreal Software, Norway). 
 
2.2. Western Blot Analysis 
Control or treated hearts were subjected to 20 min stabilization, 35 min global 
ischaemia followed by 15 min reperfusion. At this point, hearts were snap frozen in 
liquid nitrogen and stored at -80°C. Cytosolic and nuclear or mitochondrial 
extractions were performed as previously described (Lecour et al., 2005b). 
Phosphorylated and total levels of STAT-3, Akt, ERK, and FOXO-1, were analysed 
by sodium dodecyl sulphate polyacrylamide gel immunoelectrophoresis (SDS-
PAGE). Equal loading was verified by measuring levels of β-actin (cytosol/nucleus) 
or VDAC (mitochondria). Densitometry analysis was carried out using Image J 
software. A minimum of four hearts per group were used. 
 
2.3. Chemicals and pharmacological agents 
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich chemicals, 
Germany. HDL was extracted from the blood of healthy patients, as described earlier 
in section C. Western blot antibodies were obtained from Cell Signaling 
Technologies, USA. 
 
2.4. Statistical analysis 
Data are expressed as mean values ± S.E.M and were analysed by performing 
multiple group comparisons using one way ANOVA and followed by Student-
Newman-Keuls post hoc test or T-test (Graph Pad Instat).  A value of P<0.05 was 

















3.1. TNFα and STAT-3 are essential for HDL induced protection 
HDL was given following global ischaemia for 7 min of reperfusion in both TNFα-/- 
and STAT-3-/- mouse hearts. In the TNF-WT, HDL significantly reduced infarct size 
(25.8 ± 3.4%) compared to the ischaemic control (IC) (Figure 49, 40.0 ± 2.5% for IC, 
P < 0.05). This beneficial effect was not observed in the TNFα-/- hearts (41.6 ± 2.2% 
for HDL vs 38.3 ± 1.5% for IC, P=ns). Similarly, HDL protected the STAT-3-WT 
hearts (23.3 ± 2.0% for HDL vs 39.8 ± 2.0% for IC, P < 0.05) but not the STAT-3 




Fig 49. HDL induced cardioprotection is dependent on the TNFα and STAT-3. The 
cardioprotective effect of HDL is abolished in TNFα deficient and cardiomycyte-specific STAT-3 
knockout mice subjected to ischaemia/reperfusion in the isolated mouse heart model. *P < 0.05 vs 
control (n = 6 per group). WT, wildtype; KO, knockout; TNF, Tumour Necrosis Factor α; STAT-3, 




















3.2. HDL activated mitochondrial STAT-3  
Phosphorylated levels of STAT-3 were measured following 7 min of HDL treatment 
during reperfusion in STAT-3 WT hearts (Figure 50). HDL decreased STAT-3 
phosphorylation in the cytosol (In arbitrary units (AU), 3.4 ± 0.3 AU for IC and 2.0 ± 
0.4 AU for HDL, p < 0.05) and this effect was associated with an increase of 
phosphorylated STAT-3 in the nucleus (1.6 ± 0.0 AU for IC and 2.4 ± 0.0 AU for AG, 
p < 0.05). 
 
Fig 50. Phosphorylated STAT-3 translocated to the mitochondria following HDL treatment. 
Phosphorylated STAT-3 levels are decreased in the cytosol and increased in the mitochondrial 
fraction in the presence of HDL. *P < 0.05 vs control (n = 4). IC, ischaemic control; STAT-3, Signal 
























3.3. TNFα and STAT-3 are essential for S1P induced cardioprotection 
To investigate the role of the SAFE pathway in S1P induced cardioprotection, the 
infarct size was measured in the isolated perfused hearts of TNFα and STAT-3 
knockout mice and their respective littermate controls following S1P administration 
and subsequent reperfusion (Figure 51). S1P reduced the infarct size in the TNF-WT 
from 32 ± 2.1% in the ischaemic control (IC) group to 12.1 ± 2.5% for S1P (P < 0.05, 
Fig. 1). In contrast, S1P failed to reduce the infarct size in TNFα-/- (34.1 ± 2.0% for 
S1P vs 31.1 ± 1.8% for IC, P=ns). Similarly, S1P significantly reduced infarct size in 
STAT-3-WT hearts (12.1 ± 2.5% for S1P vs 32.2 ± 2.1% for IC, P < 0.05) but not in 
the STAT3-/- (34.2 ± 4.3% for S1P vs 30.2 ± 2.7% for IC, P = ns). 
 
Fig 51. S1P requires TNFα and STAT-3 to confer cardioprotection. The cardioprotective effect of 
S1P is abolished in TNFα deficient and cardiomycyte-specific STAT-3 knockout mice subjected to 
ischaemia/reperfusion in the isolated mouse heart model. *P < 0.05 vs control (n = 6 per group). WT 
wildtype, KO knockout, TNF Tumour Necrosis Factor α, STAT-3 Signal transducer and activator of 






















3.4. Pharmacological inhibition of STAT-3 abrogates the protective effect of 
S1P 
To further confirm the involvement of STAT-3 in S1P induced protection against 
reperfusion injury, we measured the infarct size in STAT-3-WT hearts perfused with 
an inhibitor for the JAK/STAT-3 pathway (AG490) during the first 15 min of 
reperfusion (Figure 52). Addition of AG490 (AG) abolished the infarct-sparing effect 
of S1P (34.1 ± 3.3% for S1P+AG vs 17.5 ± 2.2% for S1P, P < 0.05). There was no 
significant difference in infarct size between the IC and AG groups (41.8 ± 2.7% for 
IC and 31.1 ± 5.1% for AG). 
 
Fig 52. JAK/STAT-3 inhibitor, AG490 blocks S1P induced protection. Addition of the STAT-3 
inhibitor AG490 (100 nmol/L) with S1P abolished the infarct sparing effect of S1P. *P < 0.05 vs control 
(n = 6). IC, ischaemic control; STAT-3, Signal transducer and activator of transcription-3; S1P, 






















3.5. S1P increases nuclear phosphorylated STAT-3 
Furthermore, the levels of STAT-3 were measured after 15 min of reperfusion in both 
cytosolic and nuclear fractions. S1P treatment was associated with a decrease of 
cytosolic phosphorylated STAT-3 (from 1.2 ± 0.1 AU for IC to 0.8 ± 0.1 AU for S1P, 
P < 0.05, Figure 53). Similarly, addition of AG490 reduced STAT-3 levels alone, and 
in tandem with S1P (0.8 ± 0.1 AU for S1P+AG and 0.6 ± 0.2 AU for AG). In contrast, 
S1P treatment was associated with an increase of phosphorylated STAT-3 in the 
nucleus (0.5 ± 0.1 AU for IC to 1.0 ± 0.2 AU for S1P, P < 0.05). This effect was 
abolished with addition of AG490 (0.4 ± 0.1 AU for S1P+AG) and similarly, AG alone 




Fig 53. S1P induces nuclear translocation of phosphorylated STAT-3. S1P decreased 
phosphorylation of cytosolic STAT-3 and increased levels of phosphorylated STAT-3 in the nucleus. 
*P < 0.05 vs control (n = 4). IC, ischaemic control; STAT-3, Signal transducer and activator of 




















3.6. S1P activates mitochondrial STAT-3  
We compared the phosphorylated levels of STAT-3 in cytosolic and mitochondrial 
fractions in S1P treated hearts after 7 min or 15 min of reperfusion. Phosphorylated 
STAT-3 levels were significantly increased with S1P in the mitochondria after 7 min 
of reperfusion (0.9 ± 0.1 AU for IC to 1.3 ± 0.1 AU for S1P, P < 0.05, Figure 54a). In 
contrast, there was a marked reduction in phosphorylated STAT-3 levels observed 
with S1P in the mitochondria after 15 min of reperfusion (1.7 ± 0.2 AU for IC to 0.9 ± 
0.1 AU for S1P, P < 0.05, Figure 54b). In the cytosolic fraction, pretreatment with 
S1P was associated with a decrease in STAT-3 phosphorylation at both 7 min and 
15 min of reperfusion (0.9 ± 0.0 AU for IC to 0.7 ± 0.0 AU for S1P, P < 0.05, Figure 


















Fig 54. Mitochondrial translocation of STAT-3 is induced by S1P. a Increased phosphorylation of 
STAT-3 in the mitochondria at 7 min reperfusion *P < 0.05 vs control (n = 4). b Representative 
western blot demonstrating decreased levels of phosphorylated STAT-3 in the mitochondria at 15 min 
reperfusion *P < 0.05 vs control (n = 4). c Phosphorylated STAT-3 are decreased in the cytosol at 7 
min reperfusion *P < 0.05 vs control (n = 4). d Western blot analysis revealed a decreased levels of 
phosphorylated STAT-3 in the cytosol at 15 min reperfusion *P < 0.05 vs control (n = 4). IC ischaemic 



















3.7. Inhibition of Akt but not ERK abrogates the protective effect of 
Sphingosine-1-Phosphate 
To investigate the involvement of the RISK pathway in S1P induced protection 
against reperfusion injury, infarct size was measured in STAT-3-WT hearts perfused 
with either wortmannin, an inhibitor of the PI-3 kinase/Akt pathway (W), or PD98059, 
an inhibitor of Mek/Erk1/2 (PD). Addition of wortmannin abolished the infarct-sparing 
effect of S1P (37.1 ± 4.8% for S1P+W vs 17.5 ± 2.2% for S1P, P < 0.05, Figure 55). 
There was no significant difference in infarct size between the IC and W groups 
(41.8 ± 2.7% for IC and 36.1 ± 5.0% for W, P = ns). Interestingly, addition of PD did 
not significantly abolish the protective effect of S1P (22.3 ± 6.1% for S1P+PD vs IC, 
P < 0.05). PD alone, had no effect on infarct size (30.3 ± 10.7% vs IC, P = ns).    
 
Fig 55. Akt but not, Erk inhibitors abrogate the protective effect of S1P in WT mice. Inhibiting 
the activation of Akt (by wortmannin) and Erk (by PD98059) during early reperfusion abrogates the 
protective effect of S1P in wildtype mice. *P<0.05 vs control (n = 6 per group). IC ischaemic control, 
















3.8. Levels of Akt, Erk and STAT-3 in S1P treated hearts 
We examined the cytosolic and nuclear levels of Akt, Erk and STAT-3 during the first 
15 min of reperfusion after S1P administration. Phosphorylated Akt levels were 
significantly decreased in the cytosolic S1P group compared to the IC group (2.8 ± 
0.5 AU for IC vs 1.4 ± 0.3 AU for S1P, P < 0.05, Figure 56a). In contrast, nuclear 
levels of phosphorylated Akt were increased (1.1 ± 0.1 AU for IC vs 1.9 ± 0.4 AU for 
S1P, P < 0.05).  Wortmannin and PD98059, alone showed reduced levels of 
phosphorylated Akt in both cytosolic (1.2 ± 0.2 AU for W, and 1.0 ± 0.2 AU for PD vs 
IC, P < 0.05) and nuclear fractions (1.4 ± 0.3 AU for W and 1.0 ± 0.2 AU for PD vs 
IC, P = ns). Similarly, co-treatment of S1P with Akt or Erk inhibitors exhibited lower 
levels of Akt in both the cytosolic (1.5 ± 0.6 AU for S1P+W; 1.2 ± 0.4 AU for S1P+PD 
vs IC, P < 0.05) and nuclear fractions (1.2 ± 0.3 AU for S1P+W and 1.1 ± 0.2 AU for 
S1P+PD vs IC, P = ns).  
Cytosolic levels of phosphorylated Erk were slightly reduced with S1P treatment (1.7 
± 0.1 AU for IC vs 1.4 ± 0.0 AU for S1P, P = ns, Figure 56b) but increased in the 
nuclear fraction, compared to their respective control (1.1 ± 0.2 AU for IC vs 1.8 ± 
0.4 AU for S1P, P < 0.05). There was no significant change in phosphorylated Erk 
levels observed in the wortmannin (alone) treated groups from either cytosolic (1.3 ± 
0.2 AU for W vs IC, P = ns) or nuclear fraction (1.5 ± 0.2 AU for W vs IC, P = ns). 
However, PD98059 control group was significant decreased in the cytosol compared 
to the ischaemic control (1.0 ± 0.1 AU for PD vs IC, P < 0.05). This effect was not 
observed in the nuclear fraction (1.0 ± 0.2 AU for PD vs IC, P = ns). Co-treatment of 
S1P and W did not significantly alter Akt levels in either cytosolic (1.4 ± 0.2 AU for 
S1P+W vs IC, P = ns) or nuclear fractions (1.5 ± 0.1 AU for S1P+W, P = ns). S1P, 
together with PD, exhibited significantly lower levels of cytosolic phosphorylated Erk 
levels compared with the IC group (1.1 ± 0.1 AU for S1P+PD vs IC, P < 0.05). In 
contrast, phosphorylated levels of Akt obtained from the S1P and PD treated group 
were at basal levels in the nuclear fraction (1.1 ± 0.1 AU for S1P+PD vs IC, P = ns).  
Cytosolic STAT-3 levels were decreased in the S1P group compared to the IC 
group, as previously reported in section 3.5 (2.7 ± 0.3 AU for IC to 1.1 ± 0.1 AU for 
S1P, P < 0.05, Figure 56c). In contrast, phosphorylated levels of nuclear STAT-3 
















to 2.1 ± 0.4 AU for S1P, P < 0.05). Both W and PD inhibitors significantly decreased 
levels of phosphorylated STAT-3 in the cytosolic fraction (1.4 ± 0.3 AU for W and 1.1 
± 0.2 AU for PD vs IC, P < 0.05). There was no change in nuclear levels of 
phosphorylated STAT-3 in either W or PD group (1.5 ± 0.2 AU for W and 1.0 ± 0.2 
AU for PD vs IC, P = ns). The S1P+W and S1P+PD cytosolic groups showed 
significantly decreased phosphorylated STAT-3 levels (1.0 ± 0.2 AU for S1P+W and 
1.4 ± 0.3 AU for S1P+PD vs IC, P < 0.05) but there was not change observed in the 
nuclear groups compared with their respective IC groups (1.5 ± 0.1 AU for S1P+W 

































Fig 56. Phosphorylation of Akt, Erk and STAT-3 in WT mice. Bar graphs derived from western 
blots of cytosolic (left) and nuclear (right) fractions demonstrating phosphorylation of Akt, Erk and 
STAT-3 after 15 min reperfusion in S1P treated hearts. *P<0.05 vs control (n = 4). IC, ischaemic 
control; S1P, sphingosine 1-phosphate; W, wortmannin; PD, PD98059; STAT-3, Signal transducer 
















3.9. Levels of Akt and Erk in STAT-3-/- 
Cytosolic and nuclear levels of phosphorylated Akt and Erk were measured in 
cardiac deficient STAT-3 mice hearts treated with S1P (Figure 57). Phosphorylated 
Akt levels were not significantly altered between the IC and S1P treated groups in 
both the cytosolic (1.3 ± 0.1 AU for IC and 1.3 ± 0.1 AU for S1P, P = ns) and nuclear 
fractions (1.1 ± 0.3 AU for IC and 1.0 ± 0.1 AU for S1P, P = ns). Similarly, there was 
no increase in both cytosolic and nuclear phosphorylated Erk levels in the S1P group 
compared to the IC group (2.2 ± 0.5 AU for cytosolic IC and 2.0 ± 0.4 AU for 
cytosolic S1P; 1.6 ± 0.2 AU for nuclear IC and 1.6 ± 0.2 AU for nuclear S1P, P = ns). 
 
 
Fig 57. Phosphorylation of Akt, Erk in cardiomyocyte specific STAT-3 knockout mice. The 
absence of STAT-3 does not alter phosphorylated Akt and Erk levels in cytosolic and nuclear 
















3.10. Levels of FOXO-1 in WT and STAT-3-/- 
FOXO-1 is a known downstream target of Akt (Matsuzaki et al., 2003, Ni et al., 2007) 
and its role was examined in S1P induced cardioprotection. In WT mice, treatment 
with S1P was associated with a decrease in cytosolic phosphorylated FOXO-1 levels 
compared to the IC group (1.8 ± 0.1 AU for IC to 1.2 ± 0.1 AU for S1P, P < 0.05, 
Figure 58a). When Akt and Erk were inhibited with W or PD, S1P also decreased 
phosphorylated FOXO-1 in the cytosol (1.4 ± 0.1 AU for S1P+W, 0.9 ± 0.1 AU for W, 
0.8 ± 0.1 AU for S1P+PD and 0.9 ± 0.2 AU for PD vs IC, P < 0.05). In contrast, S1P 
treatment increased phosphorylated FOXO-1 levels in the nuclear fraction (0.8 ± 0.1 
AU for IC to 1.1 ± 0.1 AU for S1P, P < 0.05). Wortmannin and PD98059 inhibited this 
effect (0.8 ± 0.1 AU for S1P+W and 0.7 ± 0.1 AU for S1P+PD vs IC, P=ns). Neither 
W nor PD levels, alone affected FOXO-1 levels compared to the control (0.8 ± 0.1 
AU for W and 0.6 ± 0.1 AU for PD vs IC, P = ns). In STAT-3-/- mice treated with S1P, 
there was no significant change in phosphorylated FOXO-1 levels for both cytosolic 
(1.1 ± 0.1 AU for IC to 0.9 ± 0.1 AU for S1P, P = ns, Figure 58b) and nuclear (1.0 ± 


















Fig 58. Phosphorylation of FOXO-1 in WT and STAT-3
-/-
 mice. a Bar graphs derived from western 
blot of cytosolic and nuclear  fraction demonstrating phosphorylation of FOXO-1 after 15 min 
reperfusion in S1P treated hearts from WT mice. *P < 0.05 vs control (n = 4). b Phosphorlated FOXO-
1 levels did not differ in the cytosolic and nuclear fraction in S1P treated hearts from STAT-3
-/-
 mice. 
P=ns. IC, ischaemic control; S1P, sphingosine 1-phosphate; W, wortmannin; PD, PD98059; STAT-3, 





















Our data show that exogenous HDL or its cardioprotective component, sphingosine-
1-phosphate given at the onset of reperfusion confer cardioprotective against 
ischaemia/ reperfusion injury via the SAFE pathway. Hence, both HDL and S1P 
were given for 7 min during the 45 min reperfusion following 35 min of global 
ischaemia protected WT mice but failed to protect cardiomyocyte specific STAT-3 
deficient and TNFα deficient mice. Furthermore, the infarct sparing effect with S1P 
was abolished in the presence of AG490, wortmannin but not PD98059. 
Interestingly, cytosolic levels of phosphorylated of STAT-3 were decreased by all the 
inhibitors but phosphorylated levels of Akt and Erk were unchanged by S1P in the 
STAT-3-/- mice. Our data demonstrate that cardioprotection induced by S1P may be 
conferred via a potential crosstalk between the SAFE and RISK protective paths. 
 
4.1. HDL is cardioprotective against reperfusion injury via the SAFE pathway 
HDL has been shown to be protective against ischemia reperfusion injury (Calabresi 
et al., 2003, Theilmeier et al., 2006). HDL induced protection is associated with a 
reduction in cardiac TNFα levels and an increase of prostaglandins release 
(Calabresi et al., 2003). Prostaglandin release may contribute to the HDL induced 
reduction of TNFα or by exerting a vasodilatory action during reperfusion (Xiao et al., 
2001, Calabresi et al., 2003). An in vivo mouse study demonstrated that HDL and 
S1P were protective against ischaemia/ reperfusion injury via the S1P3 
lysophosphospholipid receptor and nitric oxide-dependant pathway (Theilmeier et al., 
2006). These findings correlated with our study as STAT-3 is a known inhibitor of 
nitric oxide expression by interaction with NFκB (Yu et al., 2002).  Very recently, 
Frias et al. reported that native and reconstituted HDL induced STAT-3 activation in 
ventricular cardiomyocytes via the S1P2 receptor and Erk1/2 phosphorylation (Frias 
et al., 2009). In this study we were interested whether HDL exerted its 
cardioprotective effects via the prosurvival SAFE pathway at reperfusion. Using a 
concentration of 200 µg/ml, HDL protected the isolated perfused mouse heart. This 
beneficial effect was abolished in TNF-/- and cardiac specific STAT-3-/- mice, 
therefore suggesting that both TNF and STAT-3 are critical for protection with S1P. 
















treatment at reperfusion, suggesting that HDL activation of mitochondrial STAT-3 
contributes to the cardioprotective effect.  
4.2. Cardioprotective role of S1P 
A cardioprotective role for S1P at reperfusion was first suggested by Karliner et al. 
when S1P (0.4 µM), given continuously during the 40 min of the reperfusion period 
(Vessey et al., 2008a), significantly reduced infarct size and showed an increase in 
phosphorylated levels of Akt. Our present data show that S1P, when given at a much 
lower final concentration (10 nM) for the first 7 min of reperfusion in a mouse model, 
was enough to reduce infarct size to a comparable degree observed in their rat 
model. Our choice of S1P concentration is also much lower than the physiologically 
levels of S1P which reside between 0.2 µM and 1.1 µM (Murata et al., 2000, 
Berdyshev et al., 2005), and thus limit the reported occurrence of coronary 
vasoconstriction, bradycardia and decreased blood pressure at higher S1P 
concentrations (Ohmori et al., 2003, Sanna et al., 2004, Karliner, 2004). We also 
observed this concomitant increase in phosphorylated Akt levels which affirms the 
involvement of this prosurvival kinase in S1P induced protection against reperfusion 
injury. 
 
4.3. S1P protects against reperfusion injury by activation of the SAFE pathway 
TNF is a pleiotrophic factor that exhibits both beneficial and deleterious effects. 
Previously, we have shown, that exogenous TNF can be cardioprotective against 
reperfusion injury in a time and concentration dependant manner (Lecour, 2009). 
The activation of TNF and STAT-3 which form the prosurvival SAFE pathway was 
successfully demonstrated in ischaemic postconditioning (Lacerda et al., 2009). The 
protective role of TNF was attributed to the TNF receptor 2, since receptor-specific 
deficient mice with TNF receptor 1 still intact, abolished the postconditioning effect. 
S1P failed to reduce the infarct size in TNF deficient mice indicating the involvement 
of this cytokine in mediating its protective effect. It is likely that S1P may be acting 
via the TNF receptor 2. 
An increase in phosphorylated levels of STAT-3 has previously been suggested by 
















first time to our knowledge, a similar correlation between STAT-3 and S1P at 
reperfusion. Previous cardioprotective studies with pre- and postconditioning have 
delineated an essential role for STAT-3 to confer this beneficial effect (Lacerda et al., 
2009, Lecour et al., 2005b). The presence of STAT-3 was originally identified only in 
the cytosol and nucleus but has been recently reported to also reside in the 
mitochondria (Wegrzyn et al., 2009). Although we detected phosphorylated STAT-3 
in all these fractions, an increase in STAT-3 levels was only observed at 7 min in the 
mitochondria and disappeared by 15 min. This was in contrast to our findings in the 
cytosol and nucleus, therefore suggesting that the kinetic activation of STAT-3 in the 
mitochondria differs from the kinetic activation in the nucleus. In fact, our data cannot 
identify whether STAT-3 needs to be phosphorylated first in the cytosol before it 
translocates to the mitochondria or if STAT-3 can be phosphorylated directly in the 
mitochondria. Our findings are supported by a recent study from Boengler et al., 
whereby a cardioprotective role for mitochondrial STAT-3 against ischaemia/ 
reperfusion injury was suggested, involving the stimulation of respiration and 
inhibition of the mPTP opening (Boengler et al., 2010). 
  
4.4. S1P induced cardioprotection involves the activation of Akt and FOXO-1 
but not Erk 
The RISK pathway is well established in cardioprotection studies and mediated 
primarily by activation of the PI-3 kinase-Akt and MEK-Erk paths (Tsang et al., 2004, 
Hausenloy et al., 2005a). As discussed earlier, S1P induced an increase in 
phosphorylated Akt which was inhibited by wortmannin that also prevented infarct 
size reduction. Interestingly, we did not observe a similar outcome with Erk. Frias et 
al. demonstrated a stimulatory action of S1P on Erk in ventricular cardiomyocytes 
(Frias et al., 2009). In our experiments, inhibition of Erk with PD98059 did not abolish 
infarct size but reduced phosphorylated STAT-3 levels in the nuclear fraction. Our 
results may be explained by the possible STAT-3 active in the mitochondria that 
together with available phosphorylated Akt, were sufficient to significantly reduce cell 
death. FOXO-1 is a known downstream factor of Akt (Lekli et al., 2010). Similar to 
Akt, phosphorylated FOXO-1 levels were also increased with S1P. Furthermore, we 
















activation of FOXO-1 from both the SAFE and RISK paths. However, the individual 
contribution of either prosurvival pathway to its activation was not determined and is 
unknown. 
4.5 Limitations of Study 
STAT-3 can be phosphorylated at its serine 727 and tyrosine 705 residues. 
According to the current theory, tyrosine phosphorylation by JAK2 stimulation leads 
to STAT-3 dimerisation and translocation to the nucleus where it is additionally 
phosphorylated at its serine residue causing STAT-3 to leave the nucleus (Negoro et 
al., 2000, Mascareno et al., 2001, Kurdi and Booz, 2007). Recently however, STAT-3 
has also been identified in the mitochondria phosphorylated at its serine residue. We 
examined the phosphorylated serine levels of STAT-3 in the cytosol, nucleus and 
mitochondria. It may be possible that the phosphorylated tyrosine levels of STAT-3 
do not correlate with the serine levels under similar conditions.  
Another limitation of this study is that we investigated the effect of S1P by abolishing 
STAT-3 in the nucleus and cytosol but not in the mitochondria. We have only shown 
an increase in phosphorylated STAT-3 levels with S1P in the mitochondria. Further 
studies could compare the mitochondrial respiration with S1P in the wildtype and 
STAT-3 deficient mice. 
There are three S1P receptors in the heart, namely S1P1, S1P2, and S1P3. These 
subtypes are differentially expressed across the various cells in the heart and 
several in vitro and in vivo studies provide evidence to support their cardioprotective 
role (Means and Brow , 2009). The inclusion of specific S1P receptor deficient mice 
and/ or inhibitors to our study would be useful to elucidate the upstream signalling 
mechanism leading to the activation of SAFE and RISK pathways. 
4.6 Conclusion 
High density lipoproteins (HDL) are known major plasma carriers of S1P (Argraves 
and Argraves, 2007). Sattler et al. have shown an association between S1P bound 
to HDL in healthy individuals which are decreased in coronary artery disease 
patients (Sattler et al., 2010). In addition, both HDL and S1P have been shown to 
protect against ischemia reperfusion (Theilmeier et al., 2006) and the beneficial 
















2009). Here, we show a protective signalling mechanism for S1P given at 
reperfusion that involves both the SAFE and RISK pathways (Figure 59). We can 
suggest that the beneficial effect of HDL may be attributed to the activation of this 
novel protective path. Clinical studies thus far, have been conducted with 
reconstituted HDL consisting of ApoA1 only. The addition of S1P to reconstituted 
HDL should also be considered for testing, especially in the context of ischaemic 
coronary artery disease. Future work will therefore aim at exploring this new 
protective path in HDL induced cardioprotection as this may present novel 
therapeutic opportunities against heart disease. 
 
 
Fig 59. Summary of findings. HDL and S1P were both cardioprotective and the protective effect was 
mediated by a crosstalk between the SAFE and RISK pathways. HDL, High Density Lipoprotein; S1P, 
Sphingosine 1-Phosphate; RISK, Reperfusion Injury Salvage Kinase; MEK, Mitogen activated protein 
kinase Extracellular regulated Kinase; ERK, Extracellular Regulated Kinase; PI3K, Phosphoinositol 3-
Kinase; SAFE, Survivor Activation Factor Enhancement; TNFα, Tumour Necrosis Factor alpha; JAK, 























































1.0. Concluding remarks 
Ischaemia reperfusion injury is a burden that affects a multitude of patients suffering 
from cardiovascular diseases. Experimentally, many strategies have been applied to 
reduce it harmful effects although they failed to translate to clinical practice. 
Ischaemic preconditioning (brief episodes of ischaemia and reperfusion prior to the 
prolonged ischaemic event) has limited potential as the ischaemic event cannot be 
premeditated. However, ischaemic postconditioning (brief episodes of ischaemia and 
reperfusion applied at the onset of reperfusion) is more clinically relevant and has 
been demonstrated to be nearly as powerful as preconditioning. The pitfall about 
ischaemic postconditioning is that the protocol has to be applied in a timely and 
precise manner following the ischaemic attack and adjustments may be required for 
the pathophysiology of the individual. This dilemma presents an opportunity to 
explore substitution of postconditioning induction in favour of a pharmacological 
agent that may be administered at the onset of reperfusion. 
In this thesis, we were interested in delineating the protective signalling mechanisms 
involved in ischaemic and pharmacological postconditioning. Signal transducer and 
activator of transcription-3 (STAT-3) has been demonstrated as an important 
prosurvival factor in cardioprotection and we aimed to explore its role in 
postconditioning. 
The main and novel findings are as follows: 
1. Ischaemic postconditioning conferred cardioprotection in a murine model of 
reperfusion injury and conditions such as a minor difference in age, breeding 
strategy and number of postconditioning cycles were critical parameters to 
consider that may influence the outcome of postconditioning. 
2. STAT-3 was essential for ischaemic postconditioning and mitochondrial 
translocation of the transcription factor was confirmed. 
3. Pharmacological postconditioning with bradykinin, adenosine and opioids 
induced protection that was comparable to ischaemic postconditioning. 
Bradykinin and opioids required the activation of the SAFE pathway (TNFα 
















essential to adenosine induced cardioprotection but STAT-3 was a 
prerequisite. 
4. High Density Lipoprotein (HDL) and sphingosine-1-phosphate (S1P) are 
naturally occurring compounds that conferred cardioprotection when given at 
the onset of reperfusion via activation of the SAFE pathway. S1P induced 
protection involved the activation of both RISK (Akt) and SAFE pathways. 
5. Our data confirmed the existence of possible crosstalk between multiple 
prosurvival signalling pathways that may work in parallel to exert the 
beneficial effects afforded by postconditioning. 
In summary, we demonstrate the significance of STAT-3 in ischaemic and 
pharmacological postconditioning and also implicate activation of the SAFE pathway 
in cardioprotection (Figure 60). 
 
Fig 60. Schematic of proposed cardioprotective signalling mechanisms involving the SAFE 
and RISK pathways in ischaemic and pharmacological postconditioning. SAFE, Survival 
Activation Factor Enhancement; RISK, Reperfusion Injury Salvage Kinase; mPTP, mitochondrial 
permeability transition pore; TNFα, Tumour Necrosis Factor-alpha; STAT-3, Signal Transducer and 
















2.0. Limitations of Study 
Our studies in this thesis employ the use of the Langendorff retrograde perfusion 
system which is an isolated heart model. As such, we are not aware of the 
complications that may arise in other organs and in the circulatory system, such as 
toxicity, reactive oxygen species formation and leukocyte infiltration. The effects on 
the vagal and sympathetic systems are also not considered. We would need to 
validate our experiments in vivo.  
The signalling response of the RISK and SAFE pathways was blocked with use of 
non-specific inhibitors such as wortmannin and AG490. Wortmannin inhibits the PI3-
kinase signalling path and does not act directly on Akt. AG490 is a JAK2 inhibitor 
which is located upstream of STAT-3. Since JAK2 may activate other signalling 
molecules in addition to STAT-3, blockade of this kinase is non-specific and does 
permit identification of downstream targets. 
Phosphorylation of STAT-3, Akt, ERK and FOXO-1 were investigated in the nucleus, 
cytosol and/ or the mitochondria. It is important to note that activation of these 
signalling factors in these cellular compartments may provide different effects that 
may also occur at different times. This represents a challenge to elucidate the 
correct and appropriate activation that may be required for specific downstream 
responses in the treatment and management of cardiovascular disease. 
 
3.0. Future Directions 
Many pharmacological agents demonstrated to mimic the protective effects of 
ischaemic preconditioning have also been shown to offer the similar benefits as 
postconditioning agents. It is likely that resveratrol and ethanolamine, that I have 
successfully shown as preconditioning agents would also translate to 
postconditioning agents treated at reperfusion. 
We have presented native high density lipoprotein (HDL) and sphingosine-1-
phosphate (S1P) as novel cardioprotective agents. Since S1P forms a protective 
component of HDL, it would be interesting to test ability of reconstituted HDL that 
contained a higher concentration of S1P for a desired optimal protection levels 
















this novel molecule would allow us to explore its potential long term benefits. This 
study may also be conducted in STAT-3 deficient mice to determine if over a 
sustained period, a parallel pathway may develop to compensate for the observed 
loss of acute cardioprotection.  
S1P has 3 main receptors in the heart, S1P1-3. We have shown that S1P protects via 
a crosstalk between the SAFE and RISK pathways and the use of specific agonists 
and antagonists for these receptors could provide useful information on the signalling 
cascade involved that may aid the development of novel therapeutics.   
There is a high prevalence of heart attacks occurring among obese and diabetic 
patients. It would be enlightening to investigate the ability of HDL and S1P to elevate 
depleted levels of HDL in a murine model of obesity and diabetes and its potential 
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